Compositions for targeting extracellular vesicle trafficking and methods thereof
Patent Information
- Application Number
- PCT/US2024/018162
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-20
- Filing Date
- 2024-03-01
- Publication Date
- 2024-11-28
AI Technical Summary
Current strategies for addressing SARS-CoV-2 infection are hindered by the lack of effective direct-acting antivirals, with existing treatments being time-consuming to develop and vaccines facing potential ineffectiveness due to viral escape mutants, necessitating alternative treatment approaches such as broad-spectrum antivirals and drug repurposing.
Development of human cells comprising a genetic construct lacking the SARS-CoV-2 spike, envelope, or membrane genes, which produce extracellular vesicles that can be used to identify inhibitors of viral trafficking, and the use of FIASMA drugs to target the ASM-ceramide system for antiviral activity.
Inhibiting extracellular vesicle release and targeting the ASM-ceramide system with FIASMA drugs effectively suppresses SARS-CoV-2 replication and induces an innate antiviral response, enhancing the efficacy of existing antiviral therapies like remdesivir.
Smart Images

Figure US2024018162_28112024_PF_FP_ABST
Abstract
Description
ATTORNEY DOCKET NO. 37759.0535P1 COMPOSITIONS FOR TARGETING EXTRACELLULAR VESICLE TRAFFICKING AND METHODS THEREOF CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of the filing date of U.S. Provisional Application No. 63 / 449,159, filed on March 1, 2023, and U.S. Provisional Application 63 / 612,752, filed on December 20, 2023. The content of these earlier filed applications is hereby incorporated by reference in its entirety. STATEMENT REGARDING FEDERALLY FUNDED RESEARCH
[0002] This invention was made with government support under grant number 1101 BX004516-01A1 awarded by the Veterans Affairs Health Care System. The government has certain rights in the invention. REFERENCE TO A SEQUENCE LISTING
[0003] The present application contains a Sequence Listing that is submitted concurrent with the filing of this application in XML format, containing the file name “37759_0535U3_SL.xml,” created on February 21, 2024, and having a size of 16,384 bytes. The Sequence Listing is hereby incorporated by reference pursuant into the present application in its entirety. BACKGROUND
[0004] SARS-CoV-2 is a new strain of coronavirus causing global pandemic of coronavirus disease 2019 (COVID-19). This virus has spread worldwide, causing millions of deaths with economic and societal disruptions at levels not seen for decades. During this pandemic, 88747 U.S. veterans tested for SARS-CoV-2 infection in the U.S. between February 28 and May 14, 2020. Those who tested positive for the virus have a 4.4-fold risk of death compared to those who were negative. Old age was the most potent risk factor associated with hospitalization, need for mechanical ventilation, and mortality. Other risk factors for mortality include selected preexisting medical conditions such as obesity, diabetes, heart disease, chronic kidney disease, and liver cirrhosis. FDA-approved antiviral drugs for COVID-19 do not provide a cure. Several vaccines received emergency use approval. It may take a long time to vaccinate the world population. There is a possibility that viral escape mutants may render vaccines ineffective. Thus, an urgent need exists to develop treatment strategies for SARS-CoV-2 and broad-spectrum antivirals against future emerging viruses.ATTORNEY DOCKET NO. 37759.0535P1 SUMMARY
[0005] Disclosed herein are human cells comprising a genetic construct, wherein the genetic construct comprises a SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelop gene, the membrane gene or a combination thereof, and wherein the human cells are larger in size as compared to a wild-type cell.
[0006] Disclosed herein are methods of making a human cell line comprising SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelop gene, the membrane gene or a combination thereof, the methods comprising: a) obtaining a cell-free supernatant, wherein the cell-free supernatant comprises one or more extracellular vesicles, wherein the one or more extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS- CoV-2 RNA of the extracellular vesicles does not comprise the spike gene, the envelop gene, the membrane gene or a combination thereof, from a replicating cell line comprising SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA of the replicating cell lines does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof; and b) culturing the cell- free supernatant from step a) with one or more human cells, thereby making the human cell line.
[0007] Disclosed herein are methods of identifying an agent that inhibits release of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS- CoV-2 RNA does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof, the method comprising: (a) culturing one or more of the human cells or human cell lines disclosed herein in the presence of the agent in culture media; (b) culturing one or more of the human cells or human cell lines disclosed herein in the absence of the agent in culture media; and (c) determining the number of extracellular vesicles present in the culture media, wherein the number of extracellular vesicles present in the culture media in (a) is less than the number of extracellular vesicles present in the culture media in (b) indicates that the agent inhibits the release of the extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, and wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0008] FIGS.1A-F show the BHK-21 SARS-CoV-2 subgenomic replicon. FIG.1A shows exemplary full length and subgenomic RNA constructs. FIG.1B shows light microscopy images. FIGS. FIG.1C and 1D show time dependent viral replication and protein synthesis of BHK-21ATTORNEY DOCKET NO. 37759.0535P1 replicon cell line. FIG.1E shows extracellular vesicles analysis of wild type BHK-21 and BHK- 21 replicon cells. FIG.1F shows immune fluorescent microscopy images of sub-genomic BHK- 21 replicon.
[0009] FIG.2 shows an experimental approach to generate subgenomic replicons for SARS- CoV-2 in A549 cells. G418 selection was performed after the treatment of A549 cells with infected supernatant.
[0010] FIGS.3A-C show A549 SARS-CoV-2 replicon cell line. FIG.3A shows a luciferase assay. FIG.3B shows Nsp – immunocytochemistry. FIG.3C shows light microscopy images. Light microscopy images of different A549 clones. These images are taken using different magnification. The images show that replicon cells show massive cytoskeletal rearrangements and double membrane vesicle accumulation around the nucleus due to SARS-COV-2 replication.
[0011] FIGS.4A-G show the effects of exosome inhibitors on viral replication. FIGS.4A-C show the results of luciferase and toxicity assays. FIG.4D shows Nsp immunofluorescent images. FIGS.4E-G show colony assay for testing of exosome inhibitory drug combinations.
[0012] FIG.5 shows that SARS-CoV-2 replication induces ASM / Ceramide axis that triggers exosome release.
[0013] FIGS.6A-C show exosome inhibition is well correlated with IL29-related immune response. FIGS.6A-B show extracellular vesicle analysis nu nanotracking analysis (NTA) results. FIG.6C shows ELISA results demonstrating that inhibiting extracellular vesicle production stimulate type III interferon production.
[0014] FIG.7 shows antiviral activity of EV inhibitors as determined by nanoluciferase activity in A549 replicon cells.
[0015] FIG.8 shows antiviral activity of EV inhibitors determined by colony assay.
[0016] FIG.9 shows that ceramide and acid sphingomyelinase (ASM) expression levels on cells replicating SARS-CoV-2 sub-genomic RNA. FIASMA drug desipramine inhibited ASM in cells in A549 replicon cells. Ceramide accumulation was also inhibited by desipramine.
[0017] FIG.10 shows inhibition of ASM-ceramide system by fumonisin, desipramine and myriosin blocks SARS-CoV-2 replicon replication (top panel), and remdesvir efficacy against SARS CoV-2 replicon replication improved when combined with individual drug (bottom panel).ATTORNEY DOCKET NO. 37759.0535P1
[0018] FIG.11 shows immunohistochemical staining of paraffin embedded lung sections of patients who died of COVID-19 with antibody to ceramide, ASM and dsRNA. ASM ceramide expression was induced in airway epithelium of COVID 19 patients as compared to non- COVID-19 autopsy lung tissues.
[0019] FIG.12 shows SARS-CoV-2 infection causes chronic inflammation and lung damage. K18+ / - mice were infected with 1x104TCID or 1 x105TCID of SARS-CoV-2 intranasally and body weight change was monitored. Representative images showing histological assessment of lung revealed severe inflammation in the lung as compared to uninfected saline treated animals (Images taken at 20X). DETAILED DESCRIPTION
[0020] The present disclosure can be understood more readily by reference to the following detailed description of the invention, the figures and the examples included herein.
[0021] Before the present methods and gene expression panels are disclosed and described, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.
[0022] Moreover, it is to be understood that unless otherwise expressly stated, it is in no way intended that any method set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not actually recite an order to be followed by its steps or it is not otherwise specifically stated in the claims or descriptions that the steps are to be limited to a specific order, it is in no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, and the number or type of aspects described in the specification.
[0023] All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date ofATTORNEY DOCKET NO. 37759.0535P1 the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided herein can be different from the actual publication dates, which can require independent confirmation. DEFINITIONS
[0024] As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.
[0025] The word “or” as used herein means any one member of a particular list and includes any combination of members of that list.
[0026] Ranges can be expressed herein as from “about” or “approximately” one particular value, and / or to “about” or “approximately” another particular value. When such a range is expressed, a further aspect includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” or “approximately,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. It is also understood that there are a number of values disclosed herein and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units is also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
[0027] As used herein, the terms “optional” or “optionally” mean that the subsequently described event or circumstance may or may not occur and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0028] As used herein, the term “comprising” can include the aspects “consisting of” and “consisting essentially of.”
[0029] As used herein, the term “subject” refers to the target of administration, e.g., a human. Thus the subject of the disclosed methods can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. The term “subject” also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.). In one aspect, a subject is a mammal. In another aspect, aATTORNEY DOCKET NO. 37759.0535P1 subject is a human. The term does not denote a particular age or sex. Thus, adult, child, adolescent and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
[0030] As used herein, the term “patient” refers to a subject afflicted with a disease or disorder (e.g., SARS-CoV-2 infection). The term “patient” includes human and veterinary subjects. In some aspects of the disclosed methods, the “patient” has been diagnosed with a need for treatment for a SARS-CoV-2 infection, such as, for example, prior to the administering step.
[0031] As used herein, the term “treating” refers to partially or completely alleviating, ameliorating, relieving, delaying onset of, inhibiting or slowing progression of, reducing severity of, and / or reducing incidence of one or more symptoms or features of a particular disease, disorder, and / or condition (e.g., SARS-CoV-2 infection). Treatment can be administered to a subject who does not exhibit signs of a disease, disorder, and / or condition and / or to a subject who exhibits only early signs of a disease, disorder, and / or condition for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and / or condition.
[0032] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed method and compositions belong. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present method and compositions, the particularly useful methods, devices, and materials are as described.
[0033] Publications cited herein and the materials for which they are cited are hereby specifically incorporated by reference. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such disclosure by virtue of prior invention. No admission is made that any reference constitutes prior art. The discussion of references states what their authors assert and applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of publications are referred to herein, such reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art.
[0034] The global research effort was hampered due to biosafety restrictions on working with the fully infectious SARS-CoV-2 in a laboratory. Drug discovery efforts are a time-consuming developmental process. It may take several years to develop a direct-acting antiviral that curesATTORNEY DOCKET NO. 37759.0535P1 SARS-CoV-2 infection. Due to the urgency of the ongoing COVID-19 pandemic, screening the existing broad spectrum of antiviral drugs targeting the virus or host proteins may be an alternative and quick approach to combating this deadly infection. The drug repurposing approach is a rapid and feasible strategy to identify safe-in-use-human drugs with potential anti- SARS-CoV-2 properties. The pharmacokinetics (PK) of repurposed drugs on their effective dose, treatment duration, side effects, and toxicity.
[0035] SARS-CoV-2 belongs to the broad family of viruses known as coronaviruses. It is an enveloped positive-sense single-stranded RNA virus. The virus infects the epithelial cells within the lungs by binding its membrane glycoprotein spike and the angiotensin-converting enzyme 2 (ACE2) receptor. Although SARS-CoV-2 is known to target the lung primarily, some studies show that this virus infection causes multi-organ infection in humans. After entry, the virus replicates in the cytoplasm. The virus particles are packaged into intracellular vesicles and released by exocytosis. It is worth noting that extracellular vesicle (EVs) participates in virus infection, replication, and dissemination. The production and release of EVs are important components in the pathogenesis of the positive-strand RNA viruses, including SARS-CoV-2. Coronavirus replicates in virus-induced DMVs in the cytoplasm of infected cells. Replication competent SARS-CoV-2 RNA is present within the DMVs in the infected cells, indicating that circulating extracellular vesicles are involved in the SARS-CoV-2 infection. Bioinformatics analysis of circulating EVs from COVID-19 patients showed the presence of numerous proteins involved in the coagulation, transport, complement activation, and immunity.
[0036] Sphingomyelin (SM) is the most abundant sphingolipid in mammalian cell membranes. Sphingomyelinase catalyzes the breakdown of SM to ceramide and phosphorylcholine. Acid sphingomyelinase (ASM) is one of the three lipid hydrolases in humans. ASM-ceramide signaling pathway regulates the levels of SM, which are involved in membrane homeostasis, DMV formation, and EV release. As disclosed herein, FIASMA drugs have been identified that inhibit EV trafficking and SARS-CoV-2 RNA replication in the replicon model, supporting the usefulness of the FIASMAs for the treatment of COVID-19. FIASMA drugs have good permeability across the blood-brain barrier. Further disclosed herein are the antiviral mechanism(s) of FIASMA drugs using an efficient in vitro model that can be used to develop a new class of drugs for treating severe COVID-19. For example, the most positive-stranded RNA viruses release EVs as an innate immune escape mechanism for developing a persistent viralATTORNEY DOCKET NO. 37759.0535P1 infection. SARS-CoV-2 promotes EV-release that favors virus replication and triggers inflammation and dissemination. Inhibiting EVs trafficking and release can provide an antiviral strategy for treating or preventing SARS-CoV-2 infections. COMPOSITIONS
[0037] Disclosed herein are human cells comprising a genetic SARS-CoV-2 construct that lacks one or more of the SARS-CoV-2 spike gene, envelope gene, or membrane gene. In some aspects, the genetic construct comprises a SARS-CoV-2 RNA. As used herein, the term “Subgenome” means a subset of a genome, and a “sub-genomic clone” is a clone that can propagate from a cell in which it is genetically identical. In some aspects, disclosed herein are human cells that comprise a genetic construct that comprises a sub-genomic SARS-CoV-2 RNA, wherein the sub-genomic SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof. In some aspect, the SARS-CoV-2 RNA can be replicon of the SARS-CoV-2 RNA or a replicon of the sub-genomic SARS-CoV-2 RNA. In some aspects, the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof. In some aspects, the human cells comprising the disclosed genetic construct can be larger in size than a wild-type cell. In some aspects, the human cells are replicating this sub-genomic clone undergo massive cytoskeleton modeling, accumulation of double membrane vesicles and epithelial-mesenchymal transition. In some aspects, the human cells replicating SARS-CoV-2 sub-genomic clone are larger in size as compared to a wild-type cell. The spike, envelope and membrane genes are not required for SARS-CoV-2 replication. These genes are important for making virus particles. Deleting these genes does not affect virus RNA replication. Antiviral drugs target the virus replication machinery, for example, protease and polymerase. Therefore, the sub-genomic replicon cells can be used for antiviral screen in a BSL-2 laboratory.
[0038] An example of a spike gene amino acid sequence is: MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFS NVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIV NNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMD LEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQT LLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETATTORNEY DOCKET NO. 37759.0535P1 KCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISN CVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIA DYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGST PCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKN KCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVS VITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEH VNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPT NFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDK NTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQY GDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIP FAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQN AQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAA EIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKN FTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVN NTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLN ESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCC KFDEDDSEPVLKGVKLHYT (SEQ ID NO: 1)
[0039] An example of an amino acid sequence of the S-gene: MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFS NVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIV NNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMD LEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQT LLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSET KCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISN CVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIA DYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGST PCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKN KCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVS VITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEH VNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPT NFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKATTORNEY DOCKET NO. 37759.0535P1 NTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQY GDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIP FAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQN AQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAA EIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKN FTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVN NTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLN ESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCC KFDEDDSEPVLKGVKLHYT (SEQ ID NO: 2).
[0040] An example of an amino acid sequence of the M gene is: MADSNGTITVEELKKLLEQWNLVIGFLFLTWICLLQFAYANRNRFLYIIKLIFLWLLWPV TLACFVLAAVYRINWITGGIAIAMACLVGLMWLSYFIASFRLFARTRSMWSFNPETNILL NVPLHGTILTRPLLESELVIGAVILRGHLRIAGHHLGRCDIKDLPKEITVATSRTLSYYKLG ASQRVAGDSGFAAYSRYRIGNYKLNTDHSSSSDNIALLVQ (SEQ ID NO: 3)
[0041] An example of amino acid sequence of the full length amino acid of SARS-CoV-2 is: MESLVPGFNEKTHVQLSLPVLQVRDVLVRGFGDSVEEVLSEARQHLKDGTCGLVEVEK GVLPQLEQPYVFIKRSDARTAPHGHVMVELVAELEGIQYGRSGETLGVLVPHVGEIPVA YRKVLLRKNGNKGAGGHSYGADLKSFDLGDELGTDPYEDFQENWNTKHSSGVTRELM RELNGGAYTRYVDNNFCGPDGYPLECIKDLLARAGKASCTLSEQLDFIDTKRGVYCCRE HEHEIAWYTERSEKSYELQTPFEIKLAKKFDTFNGECPNFVFPLNSIIKTIQPRVEKKKLD GFMGRIRSVYPVASPNECNQMCLSTLMKCDHCGETSWQTGDFVKATCEFCGTENLTKE GATTCGYLPQNAVVKIYCPACHNSEVGPEHSLAEYHNESGLKTILRKGGRTIAFGGCVF SYVGCHNKCAYWVPRASANIGCNHTGVVGEGSEGLNDNLLEILQKEKVNINIVGDFKL NEEIAIILASFSASTSAFVETVKGLDYKAFKQIVESCGNFKVTKGKAKKGAWNIGEQKSIL SPLYAFASEAARVVRSIFSRTLETAQNSVRVLQKAAITILDGISQYSLRLIDAMMFTSDLA TNNLVVMAYITGGVVQLTSQWLTNIFGTVYEKLKPVLDWLEEKFKEGVEFLRDGWEIV KFISTCACEIVGGQIVTCAKEIKESVQTFFKLVNKFLALCADSIIIGGAKLKALNLGETFVT HSKGLYRKCVKSREETGLLMPLKAPKEIIFLEGETLPTEVLTEEVVLKTGDLQPLEQPTSE AVEAPLVGTPVCINGLMLLEIKDTEKYCALAPNMMVTNNTFTLKGGAPTKVTFGDDTVI EVQGYKSVNITFELDERIDKVLNEKCSAYTVELGTEVNEFACVVADAVIKTLQPVSELLT PLGIDLDEWSMATYYLFDESGEFKLASHMYCSFYPPDEDEEEGDCEEEEFEPSTQYEYGATTORNEY DOCKET NO. 37759.0535P1 TEDDYQGKPLEFGATSAALQPEEEQEEDWLDDDSQQTVGQQDGSEDNQTTTIQTIVEVQ PQLEMELTPVVQTIEVNSFSGYLKLTDNVYIKNADIVEEAKKVKPTVVVNAANVYLKH GGGVAGALNKATNNAMQVESDDYIATNGPLKVGGSCVLSGHNLAKHCLHVVGPNVN KGEDIQLLKSAYENFNQHEVLLAPLLSAGIFGADPIHSLRVCVDTVRTNVYLAVFDKNL YDKLVSSFLEMKSEKQVEQKIAEIPKEEVKPFITESKPSVEQRKQDDKKIKACVEEVTTTL EETKFLTENLLLYIDINGNLHPDSATLVSDIDITFLKKDAPYIVGDVVQEGVLTAVVIPTK KAGGTTEMLAKALRKVPTDNYITTYPGQGLNGYTVEEAKTVLKKCKSAFYILPSIISNEK QEILGTVSWNLREMLAHAEETRKLMPVCVETKAIVSTIQRKYKGIKIQEGVVDYGARFY FYTSKTTVASLINTLNDLNETLVTMPLGYVTHGLNLEEAARYMRSLKVPATVSVSSPDA VTAYNGYLTSSSKTPEEHFIETISLAGSYKDWSYSGQSTQLGIEFLKRGDKSVYYTSNPTT FHLDGEVITFDNLKTLLSLREVRTIKVFTTVDNINLHTQVVDMSMTYGQQFGPTYLDGA DVTKIKPHNSHEGKTFYVLPNDDTLRVEAFEYYHTTDPSFLGRYMSALNHTKKWKYPQ VNGLTSIKWADNNCYLATALLTLQQIELKFNPPALQDAYYRARAGEAANFCALILAYCN KTVGELGDVRETMSYLFQHANLDSCKRVLNVVCKTCGQQQTTLKGVEAVMYMGTLS YEQFKKGVQIPCTCGKQATKYLVQQESPFVMMSAPPAQYELKHGTFTCASEYTGNYQC GHYKHITSKETLYCIDGALLTKSSEYKGPITDVFYKENSYTTTIKPVTYKLDGVVCTEIDP KLDNYYKKDNSYFTEQPIDLVPNQPYPNASFDNFKFVCDNIKFADDLNQLTGYKKPASR ELKVTFFPDLNGDVVAIDYKHYTPSFKKGAKLLHKPIVWHVNNATNKATYKPNTWCIR CLWSTKPVETSNSFDVLKSEDAQGMDNLACEDLKPVSEEVVENPTIQKDVLECNVKTTE VVGDIILKPANNSLKITEEVGHTDLMAAYVDNSSLTIKKPNELSRVLGLKTLATHGLAAV NSVPWDTIANYAKPFLNKVVSTTTNIVTRCLNRVCTNYMPYFFTLLLQLCTFTRSTNSRI KASMPTTIAKNTVKSVGKFCLEASFNYLKSPNFSKLINIIIWFLLLSVCLGSLIYSTAALGV LMSNLGMPSYCTGYREGYLNSTNVTIATYCTGSIPCSVCLSGLDSLDTYPSLETIQITISSF KWDLTAFGLVAEWFLAYILFTRFFYVLGLAAIMQLFFSYFAVHFISNSWLMWLIINLVQ MAPISAMVRMYIFFASFYYVWKSYVHVVDGCNSSTCMMCYKRNRATRVECTTIVNGV RRSFYVYANGGKGFCKLHNWNCVNCDTFCAGSTFISDEVARDLSLQFKRPINPTDQSSY IVDSVTVKNGSIHLYFDKAGQKTYERHSLSHFVNLDNLRANNTKGSLPINVIVFDGKSKC EESSAKSASVYYSQLMCQPILLLDQALVSDVGDSAEVAVKMFDAYVNTFSSTFNVPME KLKTLVATAEAELAKNVSLDNVLSTFISAARQGFVDSDVETKDVVECLKLSHQSDIEVT GDSCNNYMLTYNKVENMTPRDLGACIDCSARHINAQVAKSHNIALIWNVKDFMSLSEQ LRKQIRSAAKKNNLPFKLTCATTRQVVNVVTTKIALKGGKIVNNWLKQLIKVTLVFLFVATTORNEY DOCKET NO. 37759.0535P1 AAIFYLITPVHVMSKHTDFSSEIIGYKAIDGGVTRDIASTDTCFANKHADFDTWFSQRGG SYTNDKACPLIAAVITREVGFVVPGLPGTILRTTNGDFLHFLPRVFSAVGNICYTPSKLIE YTDFATSACVLAAECTIFKDASGKPVPYCYDTNVLEGSVAYESLRPDTRYVLMDGSIIQF PNTYLEGSVRVVTTFDSEYCRHGTCERSEAGVCVSTSGRWVLNNDYYRSLPGVFCGVD AVNLLTNMFTPLIQPIGALDISASIVAGGIVAIVVTCLAYYFMRFRRAFGEYSHVVAFNTL LFLMSFTVLCLTPVYSFLPGVYSVIYLYLTFYLTNDVSFLAHIQWMVMFTPLVPFWITIA YIICISTKHFYWFFSNYLKRRVVFNGVSFSTFEEAALCTFLLNKEMYLKLRSDVLLPLTQ YNRYLALYNKYKYFSGAMDTTSYREAACCHLAKALNDFSNSGSDVLYQPPQTSITSAV LQSGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYE DLLIRKSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSV LACYNGSPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVH AGTDLEGNFYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDF NLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLE DEFTPFDVVRQCSGVTFQSAVKRTIKGTHHWLLLTILTSLLVLVQSTQWSLFFFLYENAF LPFAMGIIAMSAFAMMFVKHKHAFLCLFLLPSLATVAYFNMVYMPASWVMRIMTWLD MVDTSLSGFKLKDCVMYASAVVLLILMTARTVYDDGARRVWTLMNVLTLVYKVYYG NALDQAISMWALIISVTSNYSGVVTTVMFLARGIVFMCVEYCPIFFITGNTLQCIMLVYC FLGYFCTCYFGLFCLLNRYFRLTLGVYDYLVSTQEFRYMNSQGLLPPKNSIDAFKLNIKL LGVGGKPCIKVATVQSKMSDVKCTSVVLLSVLQQLRVESSSKLWAQCVQLHNDILLAK DTTEAFEKMVSLLSVLLSMQGAVDINKLCEEMLDNRATLQAIASEFSSLPSYAAFATAQ EAYEQAVANGDSEVVLKKLKKSLNVAKSEFDRDAAMQRKLEKMADQAMTQMYKQA RSEDKRAKVTSAMQTMLFTMLRKLDNDALNNIINNARDGCVPLNIIPLTTAAKLMVVIP DYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPNLAWPLIVTALRAN SAVKLQNNELSPVALRQMSCAAGTTQTACTDDNALAYYNTTKGGRFVLALLSDLQDL KWARFPKSDGTGTIYTELEPPCRFVTDTPKGPKVKYLYFIKGLNNLNRGMVLGSLAATV RLQAGNATEVPANSTVLSFCAFAVDAAKAYKDYLASGGQPITNCVKMLCTHTGTGQAI TVTPEANMDQESFGGASCCLYCRCHIDHPNPKGFCDLKGKYVQIPTTCANDPVGFTLKN TVCTVCGMWKGYGCSCDQLREPMLQSADAQSFLNRVCGVSAARLTPCGTGTSTDVVY RAFDIYNDKVAGFAKFLKTNCCRFQEKDEDDNLIDSYFVVKRHTFSNYQHEETIYNLLK DCPAVAKHDFFKFRIDGDMVPHISRQRLTKYTMADLVYALRHFDEGNCDTLKEILVTY NCCDDDYFNKKDWYDFVENPDILRVYANLGERVRQALLKTVQFCDAMRNAGIVGVLTATTORNEY DOCKET NO. 37759.0535P1 LDNQDLNGNWYDFGDFIQTTPGSGVPVVDSYYSLLMPILTLTRALTAESHVDTDLTKPY IKWDLLKYDFTEERLKLFDRYFKYWDQTYHPNCVNCLDDRCILHCANFNVLFSTVFPPT SFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQDVNLHSSRLSFKELLVYAADPAMHA ASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNKDFYDFAVSKGFFKEGSSVELKHFF FAQDGNAAISDYDYYRYNLPTMCDIRQLLFVVEVVDKYFDCYDGGCINANQVIVNNLD KSAGFPFNKWGKARLYYDSMSYEDQDALFAYTKRNVIPTITQMNLKYAISAKNRARTV AGVSICSTMTNRQFHQKLLKSIAATRGATVVIGTSKFYGGWHNMLKTVYSDVENPHLM GWDYPKCDRAMPNMLRIMASLVLARKHTTCCSLSHRFYRLANECAQVLSEMVMCGGS LYVKPGGTSSGDATTAYANSVFNICQAVTANVNALLSTDGNKIADKYVRNLQHRLYEC LYRNRDVDTDFVNEFYAYLRKHFSMMILSDDAVVCFNSTYASQGLVASIKNFKSVLYY QNNVFMSEAKCWTETDLTKGPHEFCSQHTMLVKQGDDYVYLPYPDPSRILGAGCFVDD IVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTGHMLDMYSV MLTNDNTSRYWEPEFYEAMYTPHTVLQAVGACVLCNSQTSLRCGACIRRPFLCCKCCY DHVISTSHKLVLSVNPYVCNAPGCDVTDVTQLYLGGMSYYCKSHKPPISFPLCANGQVF GLYKNTCVGSDNVTDFNAIATCDWTNAGDYILANTCTERLKLFAAETLKATEETFKLSY GIATVREVLSDRELHLSWEVGKPRPPLNRNYVFTGYRVTKNSKVQIGEYTFEKGDYGDA VVYRGTTTYKLNVGDYFVLTSHTVMPLSAPTLVPQEHYVRITGLYPTLNISDEFSSNVA NYQKVGMQKYSTLQGPPGTGKSHFAIGLALYYPSARIVYTACSHAAVDALCEKALKYL PIDKCSRIIPARARVECFDKFKVNSTLEQYVFCTVNALPETTADIVVFDEISMATNYDLSV VNARLRAKHYVYIGDPAQLPAPRTLLTKGTLEPEYFNSVCRLMKTIGPDMFLGTCRRCP AEIVDTVSALVYDNKLKAHKDKSAQCFKMFYKGVITHDVSSAINRPQIGVVREFLTRNP AWRKAVFISPYNSQNAVASKILGLPTQTVDSSQGSEYDYVIFTQTTETAHSCNVNRFNV AITRAKVGILCIMSDRDLYDKLQFTSLEIPRRNVATLQAENVTGLFKDCSKVITGLHPTQ APTHLSVDTKFKTEGLCVDIPGIPKDMTYRRLISMMGFKMNYQVNGYPNMFITREEAIR HVRAWIGFDVEGCHATREAVGTNLPLQLGFSTGVNLVAVPTGYVDTPNNTDFSRVSAK PPPGDQFKHLIPLMYKGLPWNVVRIKIVQMLSDTLKNLSDRVVFVLWAHGFELTSMKY FVKIGPERTCCLCDRRATCFSTASDTYACWHHSIGFDYVYNPFMIDVQQWGFTGNLQSN HDLYCQVHGNAHVASCDAIMTRCLAVHECFVKRVDWTIEYPIIGDELKINAACRKVQH MVVKAALLADKFPVLHDIGNPKAIKCVPQADVEWKFYDAQPCSDKAYKIEELFYSYAT HSDKFTDGVCLFWNCNVDRYPANSIVCRFDTRVLSNLNLPGCDGGSLYVNKHAFHTPA FDKSAFVNLKQLPFFYYSDSPCESHGKQVVSDIDYVPLKSATCITRCNLGGAVCRHHANATTORNEY DOCKET NO. 37759.0535P1 EYRLYLDAYNMMISAGFSLWVYKQFDTYNLWNTFTRLQSLENVAFNVVNKGHFDGQQ GEVPVSIINNTVYTKVDGVDVELFENKTTLPVNVAFELWAKRNIKPVPEVKILNNLGVDI AANTVIWDYKRDAPAHISTIGVCSMTDIAKKPTETICAPLTVFFDGRVDGQVDLFRNAR NGVLITEGSVKGLQPSVGPKQASLNGVTLIGEAVKTQFNYYKKVDGVVQQLPETYFTQS RNLQEFKPRSQMEIDFLELAMDEFIERYKLEGYAFEHIVYGDFSHSQLGGLHLLIGLAKR FKESPFELEDFIPMDSTVKNYFITDAQTGSSKCVCSVIDLLLDDFVEIIKSQDLSVVSKVV KVTIDYTEISFMLWCKDGHVETFYPKLQSSQAWQPGVAMPNLYKMQRMLLEKCDLQN YGDSATLPKGIMMNVAKYTQLCQYLNTLTLAVPYNMRVIHFGAGSDKGVAPGTAVLR QWLPTGTLLVDSDLNDFVSDADSTLIGDCATVHTANKWDLIISDMYDPKTKNVTKEND SKEGFFTYICGFIQQKLALGGSVAIKITEHSWNADLYKLMGHFAWWTAFVTNVNASSSE AFLIGCNYLGKPREQIDGYVMHANYIFWRNTNPIQLSSYSLFDMSKFPLKLRGTAVMSL KEGQINDMILSLLSKGRLIIRENNRVVISSDVLVNN (SEQ ID NO: 4). The Genebank Accession Number of the full-length amino acid sequence of SARS-CoV-2 is: NC_045512.2.
[0042] SARS-CoV-2 is a coronavirus, and is a positive-sense single-stranded RNA virus with a linear RNA segment. The SARS-CoV-2 RNA sequences is 29,903 bases and has the NCBI genome ID: 86693. The SARS-CoV-2 RNA used in the methods disclosed herein to produce human cells and human cells comprising a genetic construct can be a replicon of SARS-CoV-2 RNA, wherein the genetic construct comprising SARS-CoV-2 RNA does not comprise the SARS-CoV-2 RNA spike gene, the SARS-CoV-2 RNA envelope gene, the SARS-CoV-2 RNA membrane gene or a combination thereof, and is thus, a sub-genomic SARS-CoV-2 RNA.
[0043] Disclosed here in are genetic SARS-CoV-2 constructs shown in FIG.1. In some aspects, the genetic SARS-CoV-2 constructs can comprise a reporter gene. In some aspects, the spike gene, envelope gene, or membrane gene can be replaced with the reporter gene. In some aspects, the reporter gene can be Nanoluciferase Reporter (NanoLuc), lacZ, cat, gfp, rfp, or luc genes. As used herein, a “reporter gene” refers to a nucleic acid sequence that is capable of encoding a detectable label. Examples of reporter genes include but are not limited to Nanoluciferase Reporter (NanoLuc), lacZ (capable of encoding β-galactosidase), cat (capable of encoding Chloramphenicol acetyltransferase), gfp (capable of encoding Green fluorescent protein), rfp (capable of encoding Red Green fluorescent protein), or luc (capable of encoding Luciferase enzyme).ATTORNEY DOCKET NO. 37759.0535P1
[0044] In some aspects, the genetic SARS-CoV-2 constructs can comprise an antibiotic gene. In some aspects, the antibiotic resistance gene can be hygromycin, kanamycin, or neomycin.
[0045] In some aspects, the human cells can further comprise a bioluminescence reporter gene. In some aspects, the bioluminescence reporter gene can be Nanoluciferase Reporter (NanoLuc) Gene. In some aspects, the bioluminescence reporter gene can be used to measure replication of SARS-CoV-2 sub genomic clone(s). In some aspects, bioluminescence reporter genes can be used as a simple and sensitive readout for viral gene expression and viral replication. The small size, bright signal and multiple detection options make this enzyme (e.g., Nanoluciferase Reporter (NanoLuc) Gene) suitable for reporter application. In some aspects, green fluorescence or red-fluorescence reporter genes can be used to directly visualize the viral replication.
[0046] In some aspects, the human cells can further comprise an antibiotic resistance gene. In some aspects, the antibiotic resistance gene can be hygromycin, kanamycin, or neomycin. In some aspects, the antibiotic resistance gene can be used to select one or more SARS-CoV-2 RNA replicons. In some aspects, the antibiotic resistance gene can be neomycin phosphotransferase gene (NeoR-G418). The neomycin phosphotransferase gene can be used to be used to make stable cell lines because it is smaller in size and easy to fuse with viral genes.
[0047] In some aspects, the human cells can be an epithelial cell. In some aspects, the human cells can be liver cells, brain cells, lung cells, gastrointestinal cells, heart cells, kidney cells, megakaryocytes or lymphocytes. In some aspects, the human cells can be human airway cells. In some aspects, the human cells can be epithelial cells obtained from non-small-cell lung cancer cell lines (e.g., CALU-3), human lung alveolar epithelial carcinoma cells (e.g., A549 cells), a brain human neuroblastoma cell lines (e.g., SK-N-SH), mouse endothelial cell lines from axillary lymph nodes (e.g., SVEC), human endothelial cell lines (e.g., HAEC), human cardiomyocyte cell lines (e.g., AC-16), liver-derived cell lines (e.g., HepG2), gastrointestinal epithelial cell line (e.g., CaCo2) and cell lines used as Wilm tumors (G-401). In some aspects, the human cells can be cells obtained from a tumor of the kidney from a child.
[0048] In some aspects, the human cells disclosed herein can be stable. In some aspects, human cells can be derived from brain cells, lung cells or endothelial cells and can support a high level replication and stably be maintained forever in the presence of growth medium supplemented with G-418 (e.g., 40 micrograms / ml).ATTORNEY DOCKET NO. 37759.0535P1
[0049] In some aspects and as disclosed herein in the Examples, BHK-21 replicons can be cultured with G-418 (e.g., 200 micrograms / ml). In some aspects, high concentration of G-418 (e.g., 200 microgram / ml) can kill the human replicons. BHK-21 replicons are a cell line that is derived from baby hamster kidney fibroblasts that are capable of replicating SARS-CoV-2 sub- genomic. In some aspects, the BHK-21 replicon RNA can comprise a gene for G-418 allowing these cells to grow in a medium supplemented with G-418. The SARS-CoV-2 RNA replication is toxic to human cells. For example, when using a medium containing 200 micrograms / ml of G- 418, human cells died. Thus, BHK-21 replicon clones could not be isolated in human cells using high concentrations of G-418. It was surprising that when a very low concentration of G-418 was used (e.g., 20-40 microgram range), human cells infected with SARS-CoV-2 could grow allowing human cells (e.g., gut, endothelial cells brain cancer cells, and lung alveolar) to be isolated. As disclosed herein, the BHK-21 replicons comprise the SARS-CoV-2 RNA which does not contain the spike, env, and / or membrane genes. In some aspects, the BHK-21 replicons comprise the SARS-CoV-2 RNA which does not contain the spike gene, the env gene, and the membrane gene.
[0050] In some aspects, the disclosed human cells can excrete one or more extracellular vesicles. In some aspects, the one or more extracellular vesicles can comprise SARS-CoV-2 RNA. In some aspects, the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof.
[0051] Extracellular vesicles are bi-lipid membrane vesicles of about 20-160 nm that are secreted by many cell types. Extracellular vesicles can be isolated from any suitable biological sample from a mammal, including but not limited to, whole blood, serum, plasma, urine, saliva, breast milk, cerebrospinal fluid, amniotic fluid, ascitic fluid, bone marrow and cultured mammalian cells, induced and non-induced pluripotent stem cells, fibroblasts, platelets, immune cells, reticulocytes, tumour cells, mesenchymal stem cells, satellite cells, hematopoietic stem cells, pancreatic stem cells, white and beige pre-adipocytes and the like. Extracellular vesicles can include specific surface markers not present in other vesicles, including surface markers such as tetraspanins, e.g., CD9, CD37, CD44, CD53, CD63, CD81, CD82 and CD151; targeting or adhesion markers such as integrins, ICAM-1, EpCAM and CD31; membrane fusion markers such as annexins, TSG101, ALIX; and other extracellular vesicle transmembrane proteins suchATTORNEY DOCKET NO. 37759.0535P1 as Rab5b, HLA-G, HSP70, LAMP2 (lysosome-associated membrane protein) and LIMP (lysosomal integral membrane protein).
[0052] Disclosed herein are extracellular vesicles derived from one or more of the human cells described herein. In some aspects, the extracellular vesicles derived from the human cells can contain replication competent sub-genomic RNA of SARS-CoV-2. In some aspects, the SARS- CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof. In some aspects, the extracellular vesicles can transfer replicating RNA to naïve cells and initiate replication.
[0053] Disclosed herein are extracellular vesicles comprising SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof. In some aspects, the extracellular vesicles further comprising a therapeutic agent. In some aspects, the extracellular vesicles are substantially cell-free. In some aspects, the extracellular vesicles have a diameter of between about 20-160 nm, such as between 30 and 150 nm, preferably a diameter of about 80- 120 nm. Also disclosed are methods of treating a subject having a SARS-CoV-2 infection, the method comprising administering to the subject a therapeutically effective amount of the extracellular vesicles disclosed herein. Methods
[0054] Disclosed herein are methods of making a human cell line comprising SARS-CoV-2 RNA. In some aspects, the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof. In some aspects, the methods can comprise a) obtaining a cell-free supernatant, wherein the cell- free supernatant comprises one or more extracellular vesicles, wherein the one or more extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA of the extracellular vesicles does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof, from a replicating cell line comprising SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA of the replicating cell lines does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof; and b) culturing the cell-free supernatant from step a) with one or more human cells, thereby making the human cell line. In some aspects, the methods can further comprise selecting one or more human cells of the human cell line that comprises SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not compriseATTORNEY DOCKET NO. 37759.0535P1 the spike gene, the envelope gene, the membrane gene or a combination thereof that express a cell marker. In some aspects, the cell marker can be a viral non-structural protein 1 (NSP1).
[0055] In some aspects, the methods can further comprise growing one or more human cells of the human cell line that comprises SARS-CoV-2 RNA, wherein the SARS-coV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof. SARS-CoV-2 can be toxic to human cells. In some aspects, the SARS-CoV-2 RNA of the replicating cell lines can be developed, and grown using low concentrations of G-418 (e.g., 20 micrograms / ml to 40 micrograms / ml). The human cells and the human cell lines can show stable virus replication. In some aspects, the human cell line can be stable. In some aspects, brains cells can be greater than 100 times support virus replication.
[0056] In some aspects, the one or more human cells can be a lung cell, a brain cell, a gut epithelial cell, or an endothelial cell. In some aspects, the human cells can be an epithelial cell. In some aspects, the human cells can be liver cells, brain cells, lung cells, gastrointestinal cells, heart cells, kidney cells, megakaryocytes or lymphocytes.
[0057] In some aspects, the human cell line can be a human alveolar basal epithelial tumor cell line (A549), a submucosal gland cell line (CALU3), a gut epithelial cell line (CACO-2), or a brain cell line (SK-N-SH, ATCC_HTB-11).
[0058] Also disclosed herein are methods of identifying an agent that inhibits release of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof. In some aspects, the methods can comprise: (a) culturing the human cell disclosed herein or the human cell line disclosed herein in the presence of the agent in culture media; (b) culturing the human cell disclosed herein or the human cell line disclosed herein in the absence of the agent in culture media; and (c) determining the number of extracellular vesicles present in the culture media. In some aspects, the number of extracellular vesicles present in the culture media in (a) is less than the number of extracellular vesicles present in the culture media in (b) indicating that the agent inhibits the release of the extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, and wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2ATTORNEY DOCKET NO. 37759.0535P1 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof.
[0059] In some aspects, the number of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS- CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof, can be determined by bioluminescence. In some aspects, the number of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof, can be determined by immunocytochemistry. In some aspects, the number of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof, can be determined by light microscopy.
[0060] Further disclosed herein are methods of treating a subject having a SARS-CoV-2 infection. In some aspects, the methods can comprise administering to the subject a therapeutically effective amount of an agent identified using the method of identifying an agent that inhibits release of extracellular vesicles, wherein the extracellular vesicles comprise SARS- CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof. In some aspects, the agent can be administered as a primary antiviral therapy, adjunct antiviral therapy, or a co-antiviral therapy, or wherein the administration comprises separate administration or co-administration of the agent with at least one other antiviral composition or with at least one other composition for treating one or more symptoms associated with the SARS-CoV-2 infection. In some aspects, the agent can be imipramine, desipramine, calpeptin, or ketotifen.
[0061] Also disclosed are methods of treating a subject having a SARS-CoV-2 infection, the method comprising administering to the subject a therapeutically effective amount of the extracellular vesicles disclosed herein. In some aspects, the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof. In some aspects, the extracellular vesicles further comprising a therapeutic agent. In some aspects, the extracellular vesicles are substantially cell-free. In some aspects, theATTORNEY DOCKET NO. 37759.0535P1 extracellular vesicles have a diameter of between about 20-160 nm, such as between 30 and 150 nm, preferably a diameter of about 80-120 nm. Kits
[0062] Disclosed herein are kits comprising genetic constructs, human cells comprising the genetic constructs, and / or extracellular vesicles derived from the human cells disclosed herein. The kits can include, for example, genetic constructs comprising a SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof. In some aspects, the kits can be used for preparing and / or generating human cell lines and / or extracellular vesicles derived from the human cells / human cell lines. The kits can comprise one or more sealed vials containing any of the cultural media, growth media, buffers, etc. as described herein. For example, the kits can comprise any of the materials for culturing the human cells or human cells to produce extracellular vesicles as described herein to perform one or more of the steps of the described methods. The kits can further include any of the agents or therapeutic agents disclosed herein. In some aspects, the kits can also comprise a suitable container means, which is a container that will not react with components of the kit, such as an Eppendorf tube, an assay plate, a syringe, a bottle, or a tube. The container may be made from sterilizable materials, such as plastic or glass.
[0063] The kits can further include an instruction sheet that outlines the procedural steps of the methods set forth herein, and will follow substantially the same procedures as described herein or are known to those of ordinary skill. The instruction information may be in a computer readable medium containing machine-readable instructions that, when executed using a computer, cause the display of a real or virtual procedure of delivering a pharmaceutically effective amount of the therapeutic agent or generating the human cells, human cell lines, and / or extracellular vesicles comprising the genetic constructs disclosed herein. EXAMPLES Example 1: SARS-CoV-2 Replication Accumulates Double-Membrane Vesicles (DMVs) and Releases Extracellular Vesicles (EVs) as an Innate Immune Escape Mechanism to Sustain Viral Replication and Spread
[0064] The innate immune system plays an important role in host defense against viral and microbial infection. Virus infection triggers extracellular vesicles release to shield the viralATTORNEY DOCKET NO. 37759.0535P1 replicative intermediates from degradation to escape immune recognition. Extracellular vesicles transport viral replicative intermediates to permissive cells to disseminate infection. SARS-CoV- 2 is a positive-strand RNA virus that shows multiorgan disease and damage, including lung, heart, brain, kidney, liver, and gastrointestinal systems. It is unclear why a small subset of individuals develops severe illnesses that can lead to respiratory distress and death.
[0065] It was tested whether stimulating innate antiviral immunity can prevent virus spread through EV trafficking using FDA-approved drugs.
[0066] Methods: Stable cell line replicating SARs-CoV-2 RNAs without spike (S), membrane (M), and envelope (E) genes in baby hamster kidney (BHK-21) cell line were used. This chimera clone contains nano luciferase and neomycin-resistant gene to select stable cell clones replicating the SARS-CoV-2 sub-genomic RNA. Human alveolar basal epithelial tumor cell lines (A549) and submucosal gland cell lines (CALU3) generated from bronchial adenocarcinoma were tested for their ability to sustain virus replication after long-term G-418 selection.
[0067] Mouse model for Severe COVID-19 Pneumonia. To study severe COVID-19 pathology, the SARS-CoV-2 infection using K18-hACE2 transgenic mice was developed. K18 transgenic mice express hACE2 in airway epithelial cells under the control of the human cytokeratin 18 (K18) promoter. K18 mice were infected with SARS-CoV-2 (2 X 105TCID50) and the mice were euthanized at 4-, 5-, 6-, and 7-days post infection (DPI). The data show that SARS-CoV-2 infection of K18 mice induced a progressive body weight loss from 4 to 7 DPI and fatality at 7 DPI, compared with infected non-transgenic wild type (WT) mice (FIG.12). This model can also be used to study long-COVID. Using this model, SARS-COV-2 has been found to be resistant to the interferons and antivirals tested, and the addition of EV-inhibitors was shown to improve the antiviral efficacy and viral cure.
[0068] Results: It was found that BHK-21-derived replicon cells (FIG.1) support robust SARS- CoV-2 RNA replication assessed by the measurement of nano luciferase and immunocytochemical staining of viral non-structural protein 1 (NSP1) and other biochemical approaches in a BSL-2 facility. The sub-genomic SARS-CoV-2 replicon cells produce double- membrane vesicles (DMV) around the nucleus and release those as extracellular vesicles to the outside (EVs). The EVs derived from replicon cells contain viral RNA and transfer self- replicating SARS-CoV-2 RNA into naïve lung epithelial cells. Using this vesicular delivery approach, a sub-genomic replicon system in human lung epithelial cells (A549, CALU-3) wasATTORNEY DOCKET NO. 37759.0535P1 established through EV-mediated transfer of replicon RNA. Human lung epithelial replicon cells were cultured permanently in a media supplemented with G418. It was also found that A549 cells support very high-level RNA replication by nano luciferase and viral protein expression demonstrated by immune staining using antibodies to Nsp1. SARS-CoV-2 replication activated ceramide and acid sphingomyelin system for DMV accumulation, virus RNA replication, and EV release. Antiviral screening of a panel of drugs targeting ceramide and acid sphingomyelinase activity (FIASMA) was performed using the SARS-CoV-2-A549 replicon cells. A number of FDA-approved antidepressant drugs: imipramine and desipramine, Ketotifen, and calpeptin inhibit EV release. Inhibition of EV-release suppressed SARS-CoV-2 replication and induced expression of interferon lambda. Drugs targeting the ASM-ceramide synthesis pathway improved the antiviral activity of remdesivir against SARS-CoV-2.
[0069] FIGS.1A-F show the BHK-21 SARS-Cov-2 subgenomic replicon. The BHK-21 replicon cell line was obtained and is described in J Virology, 2022;96(6):e02216-21. FIG.2 shows the experimental approach to generate subgenomic replicons for SARS-CoV-2 in A549 cells. G418 selection was performed after the treatment of A549 cells with infected supernatant. FIGS.3A-C show A549 SARS-CoV-2 replicon cell line. FIGS.4A-G show the effects of exosome inhibitors on viral replication. FIG.5 shows that SARS-CoV-2 replication induces ASM / Ceramide axis that triggers exosome release. FIGS.6A-C show exosome inhibition is well correlated with IL29-related immune response. FIGS.6A-B show nu nanotracking analysis results. FIG.6C show ELISA results.
[0070] Conclusion: SARs-CoV-2 replication accumulates double-membrane vesicles and releases those as extracellular vesicles. Inhibition of extracellular vesicles by FIASMA drugs induces innate antiviral response and promotes viral clearance. The overarching goal of boosting innate immunity by EV trafficking will allow effective public health intervention for SARS- CoV-2 and omicron subvariants. Example 2: Development of Sub-Genomic Replicon System for SARS-CoV-2 in Airway Epithelial Cells
[0071] SARS-CoV-2 continues to spread among veterans causing high morbidity and mortality. The COVID-19 pandemic data show that the elderly and chronically ill individuals have adverse outcomes after SARS-CoV-2 infection. The extracellular vesicle release and trafficking are innate immune escape mechanisms that promote RNA virus replication and spread. The increaseATTORNEY DOCKET NO. 37759.0535P1 in EV trafficking due to high viral replication is the cause of adverse outcomes of infection. SARS-CoV-2 replication activated the ASM-ceramide system causing an increase in EV trafficking. Extracellular vesicle inhibitors (FIASMA drugs) represent an integral antiviral approach to stimulate innate immunity and reduce virus replication, production, and dissemination. The inhibitors will work at the level of virus budding through EV trafficking and reduce systemic spread by inhibiting EV’s release. This antiviral strategy was tested whether it can stimulate intracellular interferon-lambda production by inhibiting vesicle trafficking and clearance.
[0072] Results. Replicon model for SARS-CoV-2 in lung epithelial cells has been established to test EVs-trafficking hypothesis in a BSL-2 facility.
[0073] Development of sub-genomic replicon system for SARS-CoV-2 in airway epithelial cells. To test the performance of EV-inhibitors as antiviral, a BSL-2 compatible sub-genomic replicon system for SARS-CoV-2 in BHK-21 cells was used. The model replicates a chimeric sub- genomic SARS-CoV-2 RNAs in which the spike (S) gene was replaced by nano-luciferase reporter (NanoLuc), and the envelope (E) and membrane genes (M) genes were replaced with neomycin phosphotransferase gene (Neo) (FIG.1A). This allows selection of cells that support replication of sub-genomic SARS-CoV-2 RNA with G-418 selection. This model does not produce infectious virus particle therefore can be cultured in a BSL-2 tissue culture facility. BHK-21 replicon cells (Clones 2, 3, 4, 6, 7 and 8) were cultured in DMEM supplemented with G-418 (200 µg / ml) with regular media change every 3 days. The replicon cell lines support high level of SARS-CoV-2 RNA replication, and was confirmed by the measurement of NanoLuciferase. Expression of viral protein in replicon cells was confirmed by immunofluorescence (FIGS.1C, 1D, and 1F). It was observed that the replicon cells show formation of perinuclear double membrane vesicles (DMVs) clusters, a hall mark of coronavirus replication (FIG.1B). This type of DMV clusters was not seen in BHK-21 cells without sub- genomic RNA replicon. The DMVs represent diagnostic and prognostic markers for replication of many positive stranded RNA viruses and represent as an excellent therapeutic target.
[0074] It was also examined whether DMV accumulation in the BHK-21 replicons cells due to SARS-CoV-2 RNA replication triggers extracellular vesicle (EVs) release. EVs were isolated from cell free supernatants of naïve BHK-21 and BHK-21 replicon cells by precipitation with ExoQuick reagent (Invitrogen). EV concentration was determined by nanoparticle trackingATTORNEY DOCKET NO. 37759.0535P1 analysis (NTA). The replicon cells release more EV as compared to naïve BHK-21 cells (FIG. 1E). To verify whether EV isolated from replicon cells can deliver replicon RNA into naïve lung epithelial cells and initiate RNA replication, A549, CALU-3 and 16-HBE cells were incubated with purified EVs preparation derived from BHK-21 replicon for overnight. The next day cells were washed twice with growth medium and cultured with growth media supplemented with G- 418 for selecting cell clones replicating SARS-CoV-2 sub-genomic RNA. The ability of lung epithelial cells supporting SARS-CoV-2 sub-genomic RNA replication was determined by colony formation efficiency. The three lung epithelial cells developed viable cell clones after four weeks of G-418 selection. Multiple cell clones were isolated and cultured with media supplemented with G-418 (200µg / ml).
[0075] Stable sub-genomic SARS-COV-2 RNA replication model was established in human lung epithelial cells and endothelial cells (FIG.5). High-levels of expression of nanoluciferase and expression of NSP1 is shown by immunostaining.
[0076] Inhibition of extracellular vesicle trafficking and release by FIASMA drugs inhibited replication of SARS-CoV-2 RNA. To test whether inhibiting EV-trafficking could inhibit SARS- CoV-2 RNA replication, drugs (See Table 1) were screened using the lung-epithelial cells (A549) replicating sub-genomic RNA. Initially, MTT assay was performed to determine toxicity of EV inhibitors. The concentration that does not show any cell toxicity was used to test antiviral activity against SARS-CoV-2 replicon cells. For this purpose, SARS-CoV-2 replicon cells seeded in 24-well plates without G-418 were incubated with EV-inhibitors for 72 hours. Antiviral activity was assessed by the measurement of nano-luciferase. In the primary screening, four compounds that show concentration dependent decrease of nano-luciferase were selected (FIG.7). Remdesivir (inhibitor of RdRp) and GC376 (3CL protease inhibitor) were included as positive controls. The antiviral activity of these compounds was confirmed using a more specific secondary assay that includes culturing replicon cells with media containing G418 and drug together for 72 hours. In this assay G-418 supplementation will kill the cells that loose SARSCoV-2 replicon RNA (FIG.8). Four drugs exhibiting robust antiviral activity against SARS-CoV-2 were selected. A549 replicon cells were treated with individual drugs for 24 hours, antiviral activity at the level of viral protein expression confirmed by immunofluorescence (FIG. 4D). Imipramine is an acid sphingomyelinase (ASM) inhibitor that inhibits generation of ceramide, DMVs formation and EV-release, Calpeptin is an inhibitor for cysteine proteaseATTORNEY DOCKET NO. 37759.0535P1 calpain. Calpains are involved in microvesicle formation and release through their activity on cytoskeletal protein remodeling. Ketotefen inhibit extracellular vesicle release by blocking intracellular calcium release. Table 1. Examples of EV Inhibitors. EV INHIBITORS TARGETy gy g g. m actions, their synergy antiviral mechanism was examined. A549 replicon cells were treated with combination of two drugs in a synergy assay in 24 well plate, along with G-418. As a control. cells cultured with G-418 without drug treatment were used. The results show that three compounds show synergy antiviral activity against SARS-CoV-2 replicon model determined by G-418 cell killing assay (FIGS.4E-G). Imipramine shows synergistic activity with calpeptin or ketotifen. No synergy was observed between ketotifen with calpeptin. Cell viability was not affected in the concentration of drugs used in this assay. The plate cultured drug without G-418 showed abundant cell growth. The results also show that ketotifen and calpeptin when treated with imipramine show synergistic antiviral activity demonstrating that inhibition of EVs release decreased intracellular virus RNA replication.ATTORNEY DOCKET NO. 37759.0535P1
[0078] Inhibition of EVs release induced IFN-lambda production. It was examined whether the activation of the innate antiviral program through IFN production is the reason for antiviral suppression. The impact of inhibitor treatment on EV release was examined by nanotracking analysis. The three compounds tested showed a decrease in exosome release (FIG.6B). For this reason, levels of IFNλ1 production were measured in the cell supernatants of inhibitor treated A549 replicon cells by ELISA. It was found that IFNL1 production was increased in A549 replicon cell culture when EV secretion was inhibited (FIG.6C), providing a mechanism for inhibiting EVs resulting in decreased SARS-CoV-2 RNA replication.
[0079] FIASMA drugs inhibits SARS-CoV-2 replication by targeting ASM-ceramide system. Positive-stranded RNA viruses including coronaviruses utilize host membranes to generate viral replication organelles (invaginated spherules or DMVs) to support viral RNA synthesis. DMV are a central hub for RNA synthesis, and, therefore, are antiviral targets. Ceramides formation in cell membrane induce DMV formation. Ceramides are generated in plasma membrane from sphingolipids hydrolysis by acid sphingomyelinase (ASM) enzyme. Ceramide is an important molecule in the sphingolipid metabolism, and is synthesized in the ER by de novo and salvage pathway. The ASM / ceramide system is also a target of antidepressants.
[0080] It was examined whether SARS-CoV-2 sub-genomic replicon cells induce expression ASM-ceramide. The expression levels of ceramide and ASM were found to be induced in replicon cells (FIG.9). Ceramide is produced by three different pathways in the ER: de novo biosynthesis, sphingomyelin hydrolysis and salvage pathway. It was examined whether treatment of drug that inhibit de novo ceramide synthesis (myriosin), salvage pathway (fumonisin) and sphingomyelin hydrolysis (desipramine) could have antiviral effect against SARS-CoV-2. It was found that decreased ceramide and ASM expression were achieved using desipramine (FIG.9). Then, it was examined whether inhibition of ASM and ceramide synthesis could inhibit SARS- CoV-2 RNA replication. A549 replicon cells were treated with increasing concentrations of desipramine or myriocin for 48 hours, then antiviral effect was determined by the measurement of luciferase. As shown in FIG.10, concentration dependent inhibition of SARS-CoV-2 viral RNA replication by fumonisin, desipramine and myriocin. It has been demonstrated in HCV model that the DMV protect replication complex from degradation by cellular protease and nuclease. It was tested whether inhibition of ASM-ceramide-mediated DMV formation improved antiviral efficacy of remdesivir. A549 replicon cells were treated using combination of remdesvirATTORNEY DOCKET NO. 37759.0535P1 plus fumonisin or desipramine or myriosin for 48 hours. The antiviral effect combination treatment was determined by nanoluciferase expression (FIG.10). The three drugs tested targeting the ASM-ceramide system improved efficacy of remdesivir. The activation of ASM- ceramide expression was confirmed by antibody staining using autopsy human lung tissue specimens of individual who died of COVID-19 (FIG.11).
[0081] Mouse model for Severe COVID-19 Pneumonia. To study severe COVID-19 pathology, the SARS-CoV-2 infection using K18-hACE2 transgenic mice was developed. K18 transgenic mice express hACE2 in airway epithelial cells under the control of the human cytokeratin 18 (K18) promoter. K18 mice were infected with SARS-CoV-2 (2 X 105TCID50) and euthanized the mice at 4-, 5-, 6-, and 7-days post infection (DPI).
[0082] Mouse model for chronic lung injury with low virus dose. The K18 mouse model was improved to capture severe human disease phenotype for chronic lung injury after infection with a sublethal virus dose of SARS-CoV-2 (1 X 104TCID50). The K18 mice was infected with a low dose of SARS-CoV2 (1 X 104TCID50) to develop a chronic infection model. It was found that mice infected with low dose virus lost weight initially but recovered by 12 DPI and survived longer (FIG.12). The low dose of SARS-CoV-2 causes moderate-to-severe interstitial pneumonia associated with perivascular inflammation and body weight loss that progressed to 9 DPI (less than 15% loss) and developed chronic lung injury. This model is currently used to study long-COVID.
[0083] To test the hypothesis that acid sphingomyelinase-ceramide system mediates the pathogenesis of severe COVID-19. The dramatic increase in the number of infections and death due to COVID-19 has led to the development of a model system to investigate this virus more closely. A sub-genomic replication system was developed that allows research on SARS-CoV-2 using a BSL-2 facility. Understanding the virus replication mechanism can allow an active drug discovery program. During screening a panel of EV inhibitors, it was found that antidepressant(s) block the ASM / ceramide and EV-release and inhibit SARS-CoV-2. The ASM generates ceramide by hydrolysis of the phosphorylcholine group from the sphingomyelin molecule. Ceramide induce cellular membrane deformation and DMV that support virus replication and release. Ceramides synthesis in mammalian cells occurs through three distinct metabolic pathways de novo biosynthesis, sphingomyelin (SM) hydrolysis, and salvage pathway.ATTORNEY DOCKET NO. 37759.0535P1
[0084] As disclosed herein, manipulation of ceramide metabolism can be an antiviral strategy for SARS-CoV-2. The ASM-ceramide system plays an important role in many human diseases such as obesity, NAFLD, diabetes, pulmonary inflammation, cardiovascular disease, neurodegenerative diseases, depression and hormonal disorders. It has been demonstrated that increased ASM activity in SARS-CoV-2 infected cells promotes virus replication through DMV production and microparticle release. The DMV production and microparticle release are important events in the systemic spread of infection to multiple tissues, cytokine production, and inflammation. It will be tested whether ASM-ceramide system plays an important role in virus dissemination to heart, brain, liver, kidney, and blood cells, causing multiorgan failure as revealed by autopsies of patients who died due to Covid-19. For example, the role of the ASM / ceramide system will be assessed in SARS-CoV-2 RNA replication, DMV formation, and severe COVID-19 by multiorgan dissemination.
[0085] To investigate the role of ceramide in the replication of SARS-CoV-2 replication. First, it will be examined whether SARS-CoV-2 RNA replication triggers the accumulation of ASM and ceramide using the replicon system developed in lung epithelial cells (A549, CALU-3). Antibody staining will measure ceramide accumulation in sub-genomic replicons of lung epithelial cells by immunofluorescence and flow analysis. The protein expression levels will be confirmed by Western blotting. To determine whether the ceramide synthesis is induced by SARS-CoV-2 replication, mRNA levels of genes involved in ceramide biosynthesis pathways will be examined by real-time RT-PCR. Ceramide expression levels in A549 cells and SARS- CoV-2 replicon will be compared. The fold change in ceramide levels in replicons will be compared to nano-luciferase and SARS-CoV-2 RNA levels by RT-PCR. Likewise, the expression of ASM levels in cells replicating sub-genomic replicons will be measured by immunofluorescent staining, flow cytometry, and Western blotting. The ASM / ceramide accumulation will be compared with the level of SARS-CoV-2 RNA replication over time. The induction of the ASM-ceramide system in SARS-CoV-2 replicating cells will be assessed as fold change relative to A549 cells.
[0086] Second, it will be tested whether ASM-ceramide accumulation in the sub-genomic replicon cells occurs due to increased synthesis. ASM-ceramide levels will be measured after treatment with myriocin (Myr), a selective inhibitor of SPT or fumonisinB1 (FB), a potent inhibitor of CerS, and imipramine, a potent inhibitor of ASM activity. GlycosphingolipidsATTORNEY DOCKET NO. 37759.0535P1 (GSLs) are composed of complex oligosaccharide headgroups linked to ceramide. They also play an important role in DMV formation and extracellular vesicle release during SARS-CoV-2 infection. Genz-123346 is an FDA-approved inhibitor of GSLs. In this experimental setup, A549 replicon cells will be treated with a nontoxic concentration of FB, Myr, imipramine / or Genz- 123346 for 72 hours. ASM and ceramide levels will be quantified by immunofluorescence staining followed by flow cytometry using antibodies to ceramide and ASM. The variation in ceramide level will be assessed by fold change relative to vehicle-treated control. These experiments will allow the determination of the predominant biosynthetic pathways involved in ceramide biosynthesis in SARS-CoV-2 replicon cells.
[0087] Third, it will be determined whether depleting ceramide synthesis alters SARS-CoV-2 RNA replication. To address this question, it will be assessed whether inhibiting ASM activity by imipramine ceramide synthesis by Myr or FB alters SARS-CoV-2 RNA replication or indirectly through inhibiting EV production. SARS-CoV-2 replicon A549 cells will be treated with nontoxic dose of inhibitors for 72 hours and antiviral effects of each inhibitor will determined by measuring viral RNA levels by RT-PCR and NSP1 expression and nano- luciferase. The level of viral RNA to the ceramide expression will be compared. It is expected that a decrease in ceramide synthesis will inhibit SARS-CoV-2 RNA replication and EV-release.
[0088] To investigate the role of the acid sphingomyelinase (ASM) in the replication of SARS- CoV-2 replication. The production of ceramide from sphingomyelin occurs by an enzyme called acid sphingomyelinase (ASM) coded by the SMPD1 gene. First, it will be determined whether silencing acid sphingomyelinase (ASM) activity could inhibit ceramide formation, DMV accumulation, EV-trafficking, and SARS-CoV-2 replication. For this purpose, an ASM-KO A549 cells will be prepared using CRISPR / Cas9 technology. Flow cytometry and Western blot analysis will be used to verify the ASM, sphingomyelin (SM), and ceramide expression between wild-type and ASM-KO A549 cells. The SM hydrolysis to ceramide by ASM between these two cell systems will be confirmed using a commercially available assay kit (Echelon Biosciences, K-3000). The impact of ASM / ceramide loss on EV production between the wild-type and ASM- KO-cells will be measured by nano tracking analysis (NTA). It is expected that silencing ASM activity will significantly decrease ceramide accumulation and EV production. The replication of SARS-CoV-2 in the ASM-KO and wild-type cells will be assessed using measuring nano- luciferase, G418 colony assay. It is expected that SARS-CoV-2 RNA replication will beATTORNEY DOCKET NO. 37759.0535P1 inhibited due to the loss of ASM enzyme activity and ceramide formation in lung epithelial cells. The kinetics of SARS-CoV-2 replication will be assessed in ASM-KO and wild-type A549 lung epithelial cells to determine the long-term impact of virus replication and extracellular release of SARS-CoV-2 RNA when the ASM activity was abolished.
[0089] Second, the importance of ASM for DMV formation will be investigated by transmission electron microscopy (TEM). The numbers and size of DMVs in the ASM-KO and wild type A549 replicon cells will be compared to determine whether ASM-KO cells show no DMV formation. It will then be confirmed whether the reduced number of DMVs is a direct result of ASM inhibition and not a consequence of the suppression of SARS-CoV-2 RNA replication. For this purpose, a replication-independent of DMV formation through protein expression (either NSP3 or NSP4) will be used. The number of DMV formations by NSP3 / 4 decreased in ASM-KO cells will be compared to wild-type cells. Next, the impact of ASM-KO on the biosynthesis of ceramide-mediated DMV formation and distribution of dsRNA and DMV morphology will be determined. Vesicles will be isolated by detergent (1% Triton-X-100) treatment and membrane flotation by discontinuous sucrose gradient centrifugation. An equal volume of fractions will be analyzed by Western blot using an antibody against NSP1, dsRNA, caveolin2, markers for DRM, co-fractioned in the top fraction (fraction 1), and calnexin, a marker for detergent soluble membrane (DSM), localized primarily at the bottom fractions. It is expected that SARSCoV-2 RNA replication complex will be associated with detergent-resistant membrane (DRM) known as lipid-rafts. TEM will be carried out to compare the size of DMVs to determine the deformation and shrinkage of DMVs due to ASM loss.
[0090] Third, it will be determined whether overexpression of ASM or ceramide supplementation in ASM-KO cells rescues the SARS-CoV-2 RNA replication. To test the role of ASM on SARS-CoV-2 RNA replication, ASMKO cells will be transfected with ASM construct (that express wild-type ASM). The impact of ASM protein expression on SARS-CoV-2 RNA replication will be compared between wild-type and ASM-KO cells by nanoluciferase. It is expected that overexpression of ASM should rescue SARS-CoV-2 RNA replication. To test whether diminished ceramide levels affect SARS-CoV-2 replication, intracellular ceramide levels in ASK-KO A549 cells and wild-type A549 replicon cells will be measured by confocal microscopy after staining with antibody to ceramide. The ceramide level will be negligible in ASM-KO cells. To study role of ceramide on SARS-CoV-2 RNA replication, ASM-KO cellsATTORNEY DOCKET NO. 37759.0535P1 and wild-type SARS-CoV-2 replicon cells will be treated with C6-ceramide, a synthetic cell- permeable ceramide analog, and the virus replication will be measured by nano-luciferase. Exogenous C6-ceramide activates de novo ceramide biosynthesis in A549 cells. In this process, the C6-ceramide gets deactivated, and its sphingosine base gets reactivated by CerS to produce endogenous long-chain ceramides. In this experiment, cells will be treated with increasing concentrations of exogenous C6-ceramide (10, 20, and 30 mM) for 24 hours, and virus replication will be measured by nano-luciferase. An MTT assay will be performed to assess the toxicity of C6-ceramide treatment in A549 replicon cells. Ceramide levels in the treated and untreated cells will be measured by using immunofluorescent ceramide staining. It is expected that increased supplementation of ceramide will stimulate SARS-CoV-2 RNA replication and nano-luciferase.
[0091] To test whether acid sphingomyelinase (ASM) deficiency attenuates SARS-CoV-2 induced COVID-19 in mouse model. ASM knockout mice are protected from obesity-induced liver steatosis and bleomycin-induced lung inflammation and fibrosis. Many clinically approved antidepressant medications functionally inhibit ASM called FIASMA and have been shown to inhibit SARS-CoV-2 in a randomized prospective study. The contribution of the ASM-ceramide system in the pathogenesis of COVID-19 will be investigated using a new mouse-adapted SARS-CoV-2 MA10 variant that recapitulates multiple aspects of severe COVID-19 in BALB / c mice. One-year-old ASM knockout BALB / c mice (n=10) and wild-type BALB / c (n=10) will be infected with low dose SARs-CoV-2 MA10 (104 PFU) using a standard intranasal inoculation protocol. This dose captures severe disease phenotype without excessive mortality. The infection studies will be performed biosafety level 3 (BSL-3) facility. The protective role of ASM in the development of severe Covid-19 will be investigated by examining the kinetics of lung disease through 7 days post-infection. The differences in weight loss trajectory, viral replication, and histological assessment of lung damage to the conducting airway epithelial (including bronchioles) accumulation of inflammatory cells, hypercellular thickening of the alveolar septa caused by infiltrating immune cells, pneumocyte degeneration, endothelial damage will be examined.
[0092] To test the activation of sphingomyelinase-ceramide pathway in postmortem lung specimens of humans with severe COVID-19. It has been found that SARS-CoV-2 RNA replication in airway epithelial cells (A549, CALU-3) causes a dramatic reorganization ofATTORNEY DOCKET NO. 37759.0535P1 cellular membranes that look like perinuclear clusters of double-membrane vesicles (DMVs). The DMVs are resembling the size of extracellular vesicles. The DMVs contain viral replicative intermediates and relevant host factors for viral RNA replication. The DMVs hide the replicative viral RNA, leading to the escape from the innate immune sensors that generate interferon response. The release of DMVs promotes the virus’s systemic spread, leading to multiorgan virus replication and damage. DMVs are considered abnormal organelles and they do not exist under normal conditions. It will be tested whether activation of the sphingomyelinase-ceramide pathway plays an important role in the pathogenesis of COVID-19. The activation of the ASM / ceramide system will be confirmed by antibody staining using formalin-fixed lung tissue from autopsy samples of humans (n=25) who died of severe Covid-19. As a control, lung tissue of patients who died of non-COVID-19 related (n=25) will be used. Paraffin blocks of lung sections and control lung tissue sections will be obtained. First, a microscopic examination of the tissue will be performed using hematoxylin and eosin-stained slides. Immunohistochemical evaluation of ASM / ceramide expression in the lung tissue will be compared by staining with an antibody to SARS-CoV-2 spike protein. Slides will be evaluated blindly by two pathologists to determine the association of the level of viral protein expression with the expression of ASM- ceramide in the SARS-CoV-2 infected lung. The activated expression of ASM-ceramide will be verified in the control human lung tissue.
[0093] The ceramide production by sphingolipid hydrolysis through ASM triggers DMV formation and vesicular trafficking. Ceramide-induced DMVs accumulation in SARS-CoV-2 infected cells is important for sustaining virus replication. DMV represents diagnostic, prognostic, and therapeutic targets for SARS-CoV-2 infection. The results show elevated levels of ASM-ceramide in cells replicating SARS-CoV-2 and human lungs of patients who died of COVID-19. The experiments disclosed herein provide pharmaceutical and genetic approaches coupled with murine and human investigations to unravel the contribution of the ASM-ceramide system in COVID-19. If the ASM-ceramide system is involved in the viral pathogenesis, then genetic ASM deletion should prevent SARS-CoV-2 replication and severe COVID-19 in K18 mice providing a role of the ASM-ceramide system in the pathogenesis of SARS-CoV-2. Due to their conserved role in the replication cycle of +RNA viruses, it will be tested whether DMV is a target for antiviral strategies. The highly efficient replicon system will be used to performATTORNEY DOCKET NO. 37759.0535P1 biochemical approaches to understand molecular biology of ASM-ceramide system in SARS- CoV-2 replication.
[0094] To study detailed antiviral mechanisms of clinically approved FIASMA drugs using a stable sub-genomic replicon system for SARS-CoV-2 in lung epithelial cells using the BSL-2 facility. The results show that number of FIASMAs inhibiting EV-trafficking and potentially block SARS-CoV-2 RNA replication in the replicon model do not produce virus. The mechanism how FIASMA drugs are inhibiting SARS-CoV-2 RNA replication is unknown. Many tricyclic antidepressants and analogs found to inhibit ASM activity were discovered in 1970. Understanding how the FIASNA medications inhibits ASM / ceramide system, EV- trafficking and SARS-CoV-2 replication may allow repurposing these FDA approved drugs against severe Covid-19. The studies described herein will validate the antiviral activity using primary airways epithelial cells and then investigate the detailed mechanism of how the clinically licensed ASM-inhibitors block virus replication.
[0095] To study the antiviral activity of FIASMA drugs using SARS-CoV-2-infected human airways epithelial cell cultures. First, antiviral screening of FIASMA drugs listed in Table 2 will be performed using A549-SARS-CoV-2 replicon cell line. FIASMA compounds that show strong antiviral activity will be tested further using SARSCoV-2 infected primary human airways epithelial cell culture and plaque reduction assay in Vero cells in a BSL-3 lab. We developed sub-genomic replicon cell line using immortalized human bronchial epithelial cells (CALU-3). CALU-3 is a transformed pulmonary epithelial cell line. It forms a confluent sheet and polarized monolayer with tight junctions in tissue culture. This line is permissive to SARS-CoV-2. SARS- CoV-2 infection of CALU-3 cells will serve as a model system to verify the antiviral activity of FIASMA drugs using the BSL-3 facility. Drugs will be purchased from Cayman. Cells will be treated with FIASMA inhibitors at their non-toxic dose for 72 hours, and the antiviral activity will be determined by nano-luciferase assay. Virus replication will be measured in cell cultures exposed to increasing concentrations of inhibitors for 72 hours. The success of antiviral efficacy will be confirmed by more accurate methods such as G-418 cell killing assay, Western blotting, immunostaining, and viral RNA levels by qRT-PCR in the supernatants and cell pellet. The inhibitory concentration (IC50) of each drug with no observed toxicity will be determined. FDA- approved inhibitors with an excellent therapeutic index of more than 100% will be selected.ATTORNEY DOCKET NO. 37759.0535P1
[0096] Table 2. Tricyclic antidepressants (TCA) and their role as functional inhibitors of acid sphingomyelinase (FIASMA). TCA (brand name) FIASMA[ ] econ , e an v ra ac v y o se ec e compoun s w e con rme us ng w - ype SARS-CoV-2 (isolate USA-WA1,2020, NR-52281) and novel strains such as omicron subvariants using a classical plaque reduction assay in Vero cells at the BSL-3 facility. CALU-3 or Vero cells will be infected with SARS-CoV-2 virus using a standard protocol developed. To determine whether targeting ASM could inhibit omicron variants -2, infected cells will be treated with FIASMA drug or left untreated. The antiviral activity will be measured by plaque reduction assay and measuring viral RNA in the supernatants and infected cells by real-time RT-PCR. The dose-dependent antiviral activity will be examined by treating cells with increasing concentration of FIASMA drug (imipramine, desipramine and others). The antiviral activity of FIASMA drugsATTORNEY DOCKET NO. 37759.0535P1 will be confirmed by checking the expression of viral protein and expression of ACE2 by Western blotting.
[0098] Third, the antiviral activity of selected inhibitors against SARS-CoV-2 and omicron variants (BA.4 and BA.5) will be determined using infected CALU-3 cells by measuring infectious virus production. Omicron variants samples will be obtained from BEI-resources (www.BEIResources.org). The dose-dependent antiviral effect will be determined by measuring viral RNA titers in the supernatants and cell pellets by qRT-PCR. The antiviral activity of EV- inhibitors will be confirmed using SARS-CoV-2 infection of primary human bronchial epithelial cells and lung microvascular endothelial cells (lifeline technology). The antiviral activity of FISMA drugs against variants will be assayed as described herein. It is expected that selected drugs that show robust antiviral activity in replicon model will work against SARS-CoV-2 wild type virus and omicron variants since these drugs are host-targeted antivirals. Remdesivir treated culture will serve as a positive control.
[0099] Impact of FIASMA drug on initiation of SARS-CoV-2 RNA synthesis by click chemistry. First, it will assessed whether the FIASMA drugs inhibits SARS-CoV-2 replicon by preventing viral RNA synthesis. This will be determined by measurement of newly synthesized viral RNA by metabolic non-radioactive labeling in the sub-genomic replicon A549 cells in the presence and absence of FIASMA drug(s). Briefly, replicon A549 cells will be treated with 20 µM actinomycin D, an inhibitor of cellular DNA-dependent RNA transcription. Replication of SARS-CoV-2 will not be affected by this concentration of drug. After 5 hours, replicon cells will be treated with 1 mM 5-ethynyl uridine (EU, Invitrogen) or 5’ bromouridine (BrU, Sigma) for one hour. After this step, cells will be fixed with paraformaldehyde, and incorporated alkyne- modified uridine analog will be detected using click chemistry with azide-derivatized Aexa594 fluoroprobes. The BrU incorporated newly synthesized viral RNA will be detected using BrdU antibodies. These experiments will be repeated to determine whether the freshly synthesized SARS-CoV-2 RNA could be inhibited by cycloheximide (CHX), an inhibitor of protein synthesis.
[0100] Second, it will be confirmed that RNA labeling does not affect SARS-CoV-2 RNA replication. Replicon cells will be treated with various concentrations of EU (0 to 4mM) for 5 to 6 hours, and then virus replication will be measured by nano-luciferase. It is expected that RNA labeling should not have any negative effect on virus replication and luciferase expression. TheATTORNEY DOCKET NO. 37759.0535P1 final step will compare the colocalization of nascent viral dsRNA and Nsp1 by immunostaining using antibodies to dsRNA and Nsp1 will be used. The colocalization of RNA and protein complex in the presence and absence of FIASMA drug will be examined. If the FIASMA drug inhibits the level of viral RNA synthesis and replication, then it will hinder the colocalization.
[0101] Impact of FIASMA drugs on DMV formation. First, the antiviral activity of FIASMA (imipramine, desipramine) and EV-inhibitors (calpeptin, ketotifen, Y27632), preventing the formation of DMVs will be assessed by electron microscopy. DMV is 100-300 nm in diameter, and its appearance directly relates to SARS-CoV-2 replication. To obtain a global view of EV- inhibitor on cellular DMV, transmission electron microscopy will be used. The entire cytoplasm of 25 infected untreated CALU-3 cells as well as EV-inhibitor treated infected CALU-3 cells will be examined for DMV quantification. If the EV-inhibitors mechanism of action is at the level of inhibiting DMV, it is expected that the perinuclear clusters of DMV induced will be not be observed due to RNA replication. In contrast, DMV clusters will be detected in cells without inhibitor treatment. FIASMA drugs should inhibit ceramide synthesis and formation of DMVs. Double-stranded RNA (dsRNA) is indicative of coronavirus replication and is found predominantly within the inner lumen of DMVs. Immunoelectron microscopy and confocal microscopy will be performed to determine the impact of FIASMA treatment on viral RNA replication and DMV formation.
[0102] Second, experiments will be performed to exclude the possibility that the mechanism of the inhibitors is not at the level of autophagy inhibition since there are similarities of DMV with autophagy vesicles. It will be confirmed that FIASMA drugs do not inhibit rapamycin-induced autophagic vesicles. Rapamycin induce autophagy vesicles number will be measured in the presence and absence of FIASMA drugs. The ability of FIASMA inhibiting autophagy vesicles in replicon model will be quantified using LC3-GFP-RFP reporter plasmid described in our publications.
[0103] Third, it will be determined whether FIASMA drugs inhibit the biosynthesis of ceramide-mediated DMV formation and distribution of dsRNA by analyzing DMV morphology. DMVs will be isolated by detergent (1% Triton-X-100) treatment followed by membrane flotation by discontinuous sucrose gradient centrifugation. Equal volume of fractions will be analyzed by Western blot using antibody against NSP1, dsRNA, caveolin2, markers for detergent resistant membrane (DRM), co-fractioned in the top fraction (fraction 1) and calnexin,ATTORNEY DOCKET NO. 37759.0535P1 a marker for detergent soluble membrane (DSM), localized primarily at the bottom fractions. It is expected that SARS-CoV-2 RNA replication complex is associated with detergent-resistant membrane (DRM) known as lipid-rafts top fractions. TEM of the top fractions of wild type and FIASMA drug treated cells will be performed and the size of DMVs will be compared to determine the deformation and shrinkage of DMVs due to ASM loss.
[0104] Fourth, the role of DMVs to protect viral RNA and proteins involved in the replication complex from degradation will be investigated by cellular nuclease and proteases. Using gradient purified DRM fractions, it will be tested whether degradation of sphingomyelin with SMase (Sigma) increase sensitivity of NSP1 to protease treatment and the sensitivity of SARS-CoV-2 replicon RNA to RNase treatment. DRM treated with methyl-bcyclodetrin (b-CD) a compound known to extract cholesterol from membrane will be used a positive control. It will also be tested whether treatment of FIASMA with approved Covid-19 antivirals (e.g., remdesivir, molnuprevir and nirmatrelvir) increase viral cure in replicon cells. Finally, a proteomic and RNA-seq analysis of DMVs of treated and untreated cultures will be carried out to assess the impact of FIASMA drugs altering the RNA and protein composition. Many host-derived proteins such as P14P and oxysterol binding proteins are required for replication complex formation in the DMV. It is expected that additional host proteins modulated by FIASMA drug treatment involved in the antiviral activity will be identified by interfering with the assembly viral RNA in the replicating DMVs.
[0105] Impact of FIASMA drug on innate antiviral response. The innate immune activation during viral infection dictates the viral clearance and adaptive immunity to fight infection. The lung epithelial cells, the primary site of infection, are responsible for generating an innate immune response to the virus. The SARS-CoV-2 replication generates multiple viral RNA species, including double-stranded RNAs. The viral pathogen-associated molecular patterns (PAMP) recognized by cytosolic pattern recognition receptors (PRRs) are MDA5, Toll-like receptors (TLRs), a retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs).
[0106] The cytoplasmic DNA sensors. cGAS-STING and nucleotide-binding and oligomerization domain (NOD)-like receptors (NLR) are activated during SARS-CoV-2 infection due to cellular DNA damage. Cytosolic RNA sensing activates the IFN system through IRF3. Cytosolic DNA sensors activate inflammasome and inflammatory cytokine response (NF- kB). SARS-CoV-2 uses various mechanisms to escape innate immunity by blocking IRF3-ATTORNEY DOCKET NO. 37759.0535P1 mediated IFN response. SARS-CoV-2 activates the cGAS-STING pathway leading to inflammatory cytokine production through NF-kB. It has been shown that positive RNA virus replication inhibits type I IFN signaling through the degradation of interferon-alpha receptor-1 (IFNAR1), but the type III IFN pathway is unaffected. The host responses to virus infection and clearance occur concerning their type III IFN signaling. Many FIASMA drugs inhibits EV release.
[0107] First, the molecular details of activation of IFN-signaling will be investigated after blocking EV-production by FIASMA drugs in lung epithelial replicon cells (A549, CALU-3). The results will be validated using SARS-CoV-2 infected primary airway epithelial cells. IFN-b and IFN-l promoter-driven luciferase reporters will be used to measure EVs-inhibitors’ impact on the induction of IFN response. Renilla luciferase control plasmid with TK-promoter will be used as an internal control. mRNA and protein levels of type I and type III IFN will be measured with or without inhibitor treatment. TLR3 is important for the production of type I and type III IFN. TLR-3 mRNA and protein levels will be compared between EV-inhibitor treated and untreated cultures. IRF1 is important for TLR3-mediated production of type III IFN. IRF3 activation through RIG-I / MAVS / IKK / TBK is also important for type I IFN production. mRNA and protein levels of IRF-1 and IRF-3 between the treated and untreated cultures will be measured. Western blot analysis will be performed to verify the activation of RIG-I and MAVS / TBK1 in the inhibitor-treated and untreated culture.
[0108] Second, it will be investigated whether FIASMA drugs antiviral mechanism operate through cell intrinsic immunity transcription factors (IRF3 or NF-kB). It has been observed that SARS-CoV-2 replication promotes NF-kB nuclear translocation whereas IRF3 translocation is inhibited. This is the reason why SARS-CoV-2 replication shows poor activation of IFNs and ISGs but generates a high level of inflammatory cytokine response. The NF-kB nuclear translocation activates transcription of inflammatory cytokines (IL-6 and TNF-alpha). The nuclear translocation of IRF3 and NF-kB in A549 replicon cells treated with or without FIASMA drugs will be quantified. To determine whether FIASMA drug could reverse the immune activation, TNF and IL-6 mRNA levels will be compared by real-time RT-PCR in A549 replicon cells after FIASMA drug treatment. siRNA-based gene silencing approach will also be used to verify whether induction of type I and type III IFN by IRF3 or a decrease cytokine production (IL-6, TNF-alpha) through NF-kB pathway correlates with a viral replication in sub-genomicATTORNEY DOCKET NO. 37759.0535P1 replicon cells. RNA receptors including RIG-1, MDA5 and TLR3 as well as IFN receptors, will be silenced to verify their role in promoting IFN-response and decrease viral SARS-CoV-2 RNA in FIASMA treated culture.
[0109] Many FIASMA drugs approved to treat major depression and neurological pain inhibit the ASM activity. The data described herein show that desipramine inhibits ASM and SARSCoV-2 replication. It is expected that the methods disclosed herein will identify many FIASMA drugs with anti-SARS-CoV-2 activity during the screening using a replicon system. It is expected that FIAMSA drugs will block the EV release since ceramide is important for DMV formation. It will be assessed whether FIASMA drugs inhibits intracellular virus replication rather than the infection since these drugs work in the replicon model. The mechanism of how these drugs inhibit SARS-CoV-2 is unknown. The replicon model is appropriate to dissect the mechanism action of FIASMA at the level of RNA synthesis, DMV formation, EV release, and innate antiviral escape. Like other positive-stranded RNA viruses, SARS-CoV-2 reproduction, packaging, and formation DMV and their release are interrelated to EV biosynthesis and release. It is expected that blocking EV-release will accumulate viral dsRNAs; therefore, it should decrease viral replication by stimulating IFN production. Decrease virus replication will attenuate NF-kB activation in lung epithelial cells.
[0110] To study the performance of most effective FIASMA drugs for the prevention and treatment of severe COVID-19 in K18 mice infected with SARS-CoV-2 and Omicron subvariants. SARS-CoV-2 infection in humans develop acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), and post-acute sequelae of SARS-CoV-2 (PASC) or long-COVID. A large study of the VA database finds that the long-COVID is the risk factor for cardiovascular, coagulopathy, hematologic, gastrointestinal, mental health, musculoskeletal and pulmonary disorders. Understanding the mechanisms that determine the long-term outcome of veterans’ health who survived severe COVID-19 is important. Although, the approved antivirals (remdesivir and paxlovid) have improved critical care strategies and diminished the fatality rate related to SARS-CoV-2 infection, recent experience indicates that COVID-19 rebounds after treatment with Paxlovid. There is a need for next-generation broadly acting antivirals to deal with future pandemic with emerging coronaviruses. It is important to develop one or more biomarkers to stratify veterans who remains at a risk for long-COVID. Highly conserved stress- responsive enzyme acid sphingomyelinase (ASM) is activated as an adaptive response to cellularATTORNEY DOCKET NO. 37759.0535P1 stress during SARS-CoV-2 infection. ASM-ceramide system of the host cell is important for the formation of DMVs and SARS-CoV-2 RNA replication. More importantly, the DMV protects the viral replication complex from the cellular innate immune response by inhibiting the interaction of the replication complex with the host pattern recognition receptors. DMV also covers the replication complex, and, therefore, protects from cellular RNase and protease, including antiviral drugs. Many retrospective and observational studies showed FIASMA drugs treatment improves on the course of COVID-19 in humans and prevent death. The ASM- ceramide system is a potent antiviral target and biomarker for long COVID. It will be tested whether inhibiting DMV will enhance the accessibility of protease and polymerase inhibitors to the SARS-CoV-2 replication complex, therefore, allowing efficient viral suppression and cure. The performance of FIASMA drugs along with approved antiviral (Remdesivir and Nirmatrelvir, the major component of Paxlovid) will be determined using a well-established K18 mice model. This model will be used since the single cell RNA-sequencing data show that this model generates EV containing viral RNA genome and multiorgan virus dissemination. These experiments will investigate the ASM-ceramide system as a biomarker for long-COVID in a mouse model.
[0111] To test the preclinical efficacy of FIASMA drugs against SARS-CoV-2 and variants. Female and male K18 mice (total=320) will be obtained. Mice will be infected with SARS-CoV- 2 using a standard protocol. The lowest dose that caused severe disease (104 TCID50) with low mortality will be selected. A control group will be inoculated with saline. A total of 10 mice per group will be used in the antiviral testing. The in vivo safety profile, pharmacokinetics, and bioavailability of FDA-approved FIASMA drugs (Imipramine, Desipramine and others) are well known. First, a prophylactic dose-escalation study of FIASMA drugs will be performed using K18 mice. The following dose of Imipramine (0, 5, 10, 20mg / kg) and Desipramine (0, 5, 10, 20) will be used. Antiviral drugs will be administered intraperitoneally to K18 mice 2 hours before intranasal infection and the drug or vehicle treatment will be given at every 12 hours thereafter. Mice will be anesthetized with a mixture of ketamine / xylazine before intranasal infection. Body weight, viral titer and pulmonary function by whole body plethysmography (WBP) will be measured daily and compared with control group that did not receive antivirals. On day 7, animals will be sacrificed by isoflurane overdose, lung will be scored for hemorrhage and viral titer measurement.ATTORNEY DOCKET NO. 37759.0535P1
[0112] Quantitative histological assessment will be performed by a pathologist to determine whether antiviral treatment decreased the histopathological features associated lung injury due to SARS-CoV-2 replication. The histology scaring system approved by the American Thoracic Society for acute lung injury diagnosis will be used. For this purpose, three different areas of lung section will be examined at high power at 60X for the following changes: (A) Neutrophils in the alveolar space (none, 0, 1-5 cells, 1;>5 cells, 2); (B) Neutrophils in the interstitial space / septa (none,0;1-5 cells,1; >5 cells, 2); (C) Hyaline membranes (none, 0; one membrane ,1; >1,2); (D) Proteinaceous debris in air spaces (none,0; one, 1; >1, 2); and (E) Alveolar septal thickening (<2X mock thickness, 0; 2 to 4X mock thickness, 1; >4x mock thickness, 2). The score per each field determined using the formula =[20XA+14XB+7XC+7XD+2XE] / 100. The score for three field per mouse was averaged to obtain a final score. The performance of each FISMA drug will be determined by comparing the viral titer and histology score between untreated and treated animals. Since FIASMA drugs inhibits EV-release and activate innate antiviral program. Western blotting and immunostaining will be performed to confirm whether the activation of TLR-3 / IRF1, RIG-I / MAVS / TBK / IRF3 is due to accumulation of viral PAMPs. The impact of FIASMA drug treatment promoting innate immune response in the lung will be addressed. FIASMA drugs should decrease NF-kB activation and decrease inflammatory cytokine production.
[0113] Second, the best antiviral dose for FIASMA drugs that inhibit SARS-CoV-2 replication will be selected for combination treatment with remdesivir (SARS-CoV-2 polymerase inhibitor) or Nirmatrelvir (PF-332, SARS-CoV-2 protease inhibitor). It will be tested whether SARS-CoV- 2 induced DMV protect viral-replication complex accessibility to the antivirals. By inhibiting the DMV formation, the performance of COVID-19 antivirals will be improved and viral clearance will be induced. A prophylactic and therapeutic study will be performed to compare the antiviral effects of remdesivir (10, 20, 50 mg / kg) and nirmatrelvir (PF-332, 100, 200, 300 mg / kg). The best antiviral concentration in the K18 model will be selected for combination treatment with FIASMA drugs. The best antiviral dose of FIASMA drug with remdesivir or normatrelvir will be selected for combination treatment. Results of prophylactic treatment 2 hours before infection and therapeutic treatment every 12 hours will be compared. The success of combination antiviral treatment will be determined by a drop in viral RNA, reduced weight loss, mortality, acute lung injury by two-way ANOVA with Tukey’s multiple comparison test. A human autopsy studyATTORNEY DOCKET NO. 37759.0535P1 found SARS-CoV-2 RNA detected in various extrapulmonary tissue and organs. Histopathological analysis of brain, lungs, liver, heart, spleen, duodenum, and kidney will be performed by a pathologist. In-situ hybridization will be used for (+) and (-) strand RNA and immunostaining for viral N and spike antigen using paraffin-embedded tissue sections. It will be explored whether this host directed combination antiviral strategy can be used for SARS-CoV-2 variants since they escape vaccine-induced and naturally acquired immunity and transmit infection faster. Among many variants of SARS-CoV-2 (Alpha B.1.1.7, Beta B.1.351, Delta B.1.671.2 and Omicron B.1.1.529), the Omicron and Delta variants are highly contagious. They account for more than 99% of recent SARS-CoV-2 infections. A chronic lung injury model will be developed using Omicron variants in K18 mice. It will be assessed whether the combination treatment of FIASMA drugs with Remdesivir or Nirmatrelvir will prevent viral replication and reduce weight loss and acute lung damage induced by omicron subvariants in K18 mice. Omicron subvariants will be obtained from BEI resources (www.BEIRsources.org).
[0114] To test performance of FIASMA drugs in the prevention of long-COVID in experimental K18 mice. The pathophysiology of chronic lung injury in SARS-CoV-2 infection mostly relates to aberrant host cellular response to virus. The antiviral therapy targets the virus do nothing to the injured cell. Many imprints of chronic lung damage and immune exhaustion persist after virus eradication. The reversal of virus-induced lung injury is important for reducing risk of persistent disease. The lung pathology caused by SARS-CoV-2 infection of K18 mice resembles that seen in severe human COVID-19, with diffuse alveolar damage, pulmonary edema, hyaline membrane formation, and infiltration of lymphocytes into alveolar septa. K18 mice will be followed for 60 and 120 days to determine whether viral treatment resets the lung injury and reduces chronic pulmonary lesions and fibrotic response. The ASM-ceramide, ER stress and integrated stress expression in the lung tissues will be compared between mice who received no treatment, FIASMA medication vs antiviral Remdesivir or Nirmatrelvir treatment. Lung damage, sustained cytokine expression, and chronic inflammatory response (CD4+, CD8+ T cells, B220+ B cells, CD68+ macrophages) will be studied after viral treatment. The hypercellularity due to immune cell accumulation, smooth muscle actin (SMA) positive fibroblasts, and collagen deposition will be compared by Picrosirius Red staining for fibrotic lung disease as described herein. The activation of innate immunity will be assessed by the type I and type IFN III production, IRF1, IRF3, and NF-kB activation the lung tissues. Alveolar edema, cellularATTORNEY DOCKET NO. 37759.0535P1 infiltration, vascular congestion will be examined in the lung of cured and uncured animals. A large study of US veterans showed irreversible damage to heart, brain, kidney, and GI system occurs due to severe COVID-19. This model will be used to determine long-term lung, heart, liver, kidney and brain pathology after treatment with FIASMA drugs with or without COVID antivirals.
[0115] It was found that imipramine and desipramine show good antiviral activity in the replicon model; it is expected that these drugs will have excellent therapeutic utility in the mouse model. FIASMA drugs (imipramine, desipramine) are well tolerated in mice and have a good safety profile. Remdesivir is the RNA-dependent RNA polymerase inhibitor and received FDA approval, but the antiviral activity in vivo is not satisfactory. The antiviral efficacy of a newly approved protease inhibitor called Nirmatrelvir in a mouse model is not satisfactory. It is expected that inhibiting SARS-CoV-2 induced DMV should increase the access of antiviral drugs to virus replication factories, therefore, increase the antiviral potency. It is expected that combination treatment of FIASMA drug along with protease and polymerase inhibitors will show good antiviral activity in K18 mice and decrease virus replication, alveolar damage, interstitial pneumonia and multiorgan virus dissemination compared to vehicle-treated mice. The expression of proinflammatory cytokines should also be decreased, whereas antiviral cytokines, type I and type III IFN levels will be increased in the drug-treated group due to activation of innate antiviral response. It is expected this antiviral approach will work for omicron variants since they are host-directed antivirals. The mechanism of long COVID is not well understood. It is expected that persistent activation of ASM-ceramide system is one of the reasons for elevated EV-trafficking and dissemination of viral infection to multiple organ system. It will be tested whether viral elimination can reset ASM-ceramide expression. It is expected that the data obtained using the methods disclosed herein will establish a long-COVID model to study the mechanism of irreversible and reversible tissue damage during SARS-CoV-2 replication.
Claims
ATTORNEY DOCKET NO. 37759.0535P1 CLAIMS WHAT IS CLAIMED IS:
1. A human cell comprising a genetic construct, wherein the genetic construct comprises a SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV- 2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof, and wherein the human cell is larger than a wild-type cell.
2. The human cell of claim 1, further comprising a reporter gene.
3. The human cell of claim 2, wherein the reporter gene is a Nanoluciferase Reporter (NanoLuc), lacZ, cat, gfp, rfp, or luc gene.
4. The human cell of claim 1 or 2, further comprising an antibiotic resistance gene.
5. The human cell of any of the preceding claims, wherein the human cell is a human airway cell, lung cell, a brain cell, liver cell, heart cell, kidney cell, gastrointestinal cell, megakaryocyte, lymphocyte, an endothelial or an epithelial cell.
6. The human cell of any of the preceding claims, wherein the human cell is stable.
7. The human cell of any of the preceding claims, wherein the human cell excretes one or more extracellular vesicles.
8. The human cell of any of the preceding claims, wherein the one or more extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV- 2 membrane gene or a combination thereof.
9. An extracellular vesicle derived from the human cell of any of the preceding claims.
10. A method of making a human cell line comprising SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof, the method comprising: a) obtaining a cell-free supernatant, wherein the cell-free supernatant comprises one or more extracellular vesicles, wherein the one or more extracellular vesicles comprise SARS-coV-2 RNA, wherein the SARS-coV-2 RNA of the extracellular vesicles does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof, from a replicating cell line comprising SARS-CoV-2 RNA, wherein the SARS-CoV-2ATTORNEY DOCKET NO. 37759.0535P1 RNA of the replicating cell lines does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof; and b) culturing the cell-free supernatant from step a) with one or more human cells, thereby making the human cell line.
11. The method of claim 10, wherein one or more human cells are a lung cell, a brain cell, or an endothelial cell.
12. The method of claim 10, wherein the human cell line is a human alveolar basal epithelial tumor cell line (A549) or a submucosal gland cell line (CALU3).
13. The method of claim 10, further comprising selecting one or more human cells of the human cell line that comprises SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS- CoV-2 membrane gene or a combination thereof that express a cell marker.
14. The method of claim13, wherein the cell marker is viral non-structural protein 1 (NSP1).
15. The method of claim 10, further comprising growing one or more human cells of the human cell line that comprises SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS- CoV-2 membrane gene or a combination thereof.
16. The method of claim 10, wherein the human cell line is stable.
17. A method of identifying an agent that inhibits release of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof, the method comprising: a) culturing the human cell of any of claims 1 to 7 or the human cell line of any of claims 10 to 16 in the presence of the agent in culture media; b) culturing the human cell of any of claims 1 to 7 or the human cell line of any of claims 10 to 16 in the absence of the agent in culture media; and c) determining the number of extracellular vesicles present in the culture media, wherein the number of extracellular vesicles present in the culture media in (a) is less than the number of extracellular vesicles present in the culture media in (b) indicates that the agent inhibits the release of the extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, and wherein the SARS-ATTORNEY DOCKET NO. 37759.0535P1 CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof.
18. The method of claim 17, wherein the number of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS- CoV-2 membrane gene or a combination thereof, is determined by bioluminescence.
19. The method of claim 17, wherein the number of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS- CoV-2 membrane gene or a combination thereof, is determined by immunocytochemistry.
20. The method of claim 17, wherein the number of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS- CoV-2 membrane gene or a combination thereof, is determined by light microscopy.
21. A method of treating a subject having a SARS-CoV-2 infection, the method comprising administering to the subject a therapeutically effective amount of the agent identified using the method of claim 17.
22. The method of claim 21, wherein the agent is administered as a primary antiviral therapy, adjunct antiviral therapy, or a co-antiviral therapy, or wherein the administration comprises separate administration or co-administration of the agent with at least one other antiviral composition or with at least one other composition for treating one or more symptoms associated with the SARS-CoV-2 infection.
23. The method of claim 22, wherein the agent is imipramine, desipramine, calpeptin, or ketotifen.
24. An extracellular vesicle comprising SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the SARS-CoV-2 spike gene, the SARS-CoV-2 envelope gene, the SARS-CoV-2 membrane gene or a combination thereof.
25. The extracellular vesicle of claim 24, further comprising a therapeutic agent.
26. The extracellular vesicle of claim 24 or 25, wherein the extracellular vesicle is substantially cell-free.ATTORNEY DOCKET NO. 37759.0535P1 27. The extracellular vesicle of any one of claims 24-26, wherein the extracellular vesicle has a diameter of between about 20-160 nm, such as between 30 and 150 nm, preferably a diameter of about 80-120 nm.
28. A method of treating a subject having a SARS-CoV-2 infection, the method comprising administering to the subject a therapeutically effective amount of the extracellular vesicle of any one of claims 24 to 27.
Citation Information
Patent Citations
Reverse genetic system for SARS-COV-2
WO2021195596A2
